0001493152-22-016732.txt : 20220614 0001493152-22-016732.hdr.sgml : 20220614 20220614161053 ACCESSION NUMBER: 0001493152-22-016732 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20220430 FILED AS OF DATE: 20220614 DATE AS OF CHANGE: 20220614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14468 FILM NUMBER: 221014841 BUSINESS ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 619-596-8600 MAIL ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCE DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Commission File Number 001-14468

PURE Bioscience, Inc.

(Exact name of registrant as specified in its charter)

Delaware		33-0530289
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

9669 Hermosa Avenue

Rancho Cucamonga, California

91730

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (619) 596-8600

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 14, 2022, there were 88,023,141 shares of the registrant’s common stock, $0.01 par value per share, outstanding.

PURE Bioscience, Inc.

Form 10-Q

for the Quarterly Period Ended April 30, 2022

Table of Contents

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Condensed Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	24
Item 4.	Controls and Procedures	25

PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	26
Item 1A.	Risk Factors	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3.	Defaults Upon Senior Securities	27
Item 4.	Mine Safety Disclosures	27
Item 5.	Other Information	27
Item 6.	Exhibits	28
	Signatures	29

Part I - Financial Information

Item 1. Financial Statements

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets


	April 30, 2022			July 31, 2021
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	511,000		$	2,390,000
Accounts receivable		198,000			368,000
Inventories, net		301,000			332,000
Restricted cash		75,000			75,000
Prepaid expenses		25,000			32,000
Total current assets		1,110,000			3,197,000
Property, plant and equipment, net		697,000			740,000
Patents, net		311,000			366,000
Total assets	$	2,118,000		$	4,303,000
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	416,000		$	593,000
Accrued liabilities		134,000			138,000
Loan payable		—			239,000
Total current liabilities		550,000			970,000
Commitments and contingencies		-
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding		—			—
Common stock, $0.01 par value: 150,000,000 shares authorized, 88,023,141 shares issued and outstanding at April 30, 2022, and 87,223,141 shares issued and outstanding at July 31, 2021		881,000			873,000
Additional paid-in capital		128,738,000			128,253,000
Accumulated deficit		(128,051,000	)		(125,793,000	)
Total stockholders’ equity		1,568,000			3,333,000
Total liabilities and stockholders’ equity	$	2,118,000		$	4,303,000

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)


	Nine Months Ended						Three months Ended
	April 30,						April 30,
	2022			2021			2022			2021
Net product sales	$	1,409,000		$	2,841,000		$	497,000		$	556,000
Royalty revenue		32,000			227,000			27,000			5,000
Total revenue		1,441,000			3,068,000			524,000			561,000
Cost of goods sold		553,000			1,250,000			199,000			246,000
Gross profit		888,000			1,818,000			325,000			315,000
Operating costs and expenses
Selling, general and administrative		3,127,000			3,136,000			977,000			1,036,000
Research and development		255,000			265,000			107,000			89,000
Total operating costs and expenses		3,382,000			3,401,000			1,084,000			1,125,000
Loss from operations		(2,494,000	)		(1,583,000	)		(759,000	)		(810,000	)
Other income (expense)
Interest expense, net		(3,000	)		(3,000	)		(1,000	)		(1,000	)
Gain on extinguishment of indebtedness, net		239,000			—			—			—
Total other income (expense)		236,000			(3,000	)		(1,000	)		(1,000	)
Net loss	$	(2,258,000	)	$	(1,586,000	)	$	(760,000	)	$	(811,000	)
Basic and diluted net loss per share	$	(0.03	)	$	(0.02	)	$	(0.01	)	$	(0.01	)
Shares used in computing basic and diluted net loss per share		87,741,639			87,157,857			87,925,388			87,223,141

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

	Nine Months Ended April 30, 2022													Nine Months Ended April 30, 2021
	Common Stock				Additional Paid-In			Accumulated			Total Stockholders’			Common Stock				Additional Paid-In			Accumulated			Total Stockholders’
	Shares		Amount		Capital			Deficit			Equity			Shares		Amount		Capital			Deficit			Equity

Balances at beginning of period		87,223,141	$	873,000	$	128,253,000		$	(125,793,000	)	$	3,333,000			87,072,951	$	871,000	$	127,414,000		$	(123,474,000	)	$	4,811,000
Share-based compensation expense - stock options		—		—		431,000			—			431,000			—		—		621,000			—			621,000
Share-based compensation expense - restricted stock units		—		—		62,000			—			62,000			—		—		62,000			—			62,000

Issuance of common stock upon the exercise of stock options		—		—		—			—			—			150,190		2,000		(2,000	)		—			—

Issuance of common stock for vested restricted stock units		800,000		8,000		(8,000	)		—			—			—		—		—			—			—
Net loss		—		—		—			(2,258,000	)		(2,258,000	)		—		—		—			(1,586,000	)		(1,586,000	)
Balances at end of period (Unaudited)		88,023,141	$	881,000	$	128,738,000		$	(128,051,000	)	$	1,568,000			87,223,141	$	873,000	$	128,095,000		$	(125,060,000	)	$	3,908,000

	Three Months Ended April 30, 2022													Three Months Ended April 30, 2021
	Common Stock				Additional Paid-In			Accumulated			Total Stockholders’			Common Stock				Additional Paid-In		Accumulated			Total Stockholders’
	Shares		Amount		Capital			Deficit			Equity			Shares		Amount		Capital		Deficit			Equity

Balances at beginning of period (Unaudited)		87,873,141	$	879,000	$	128,617,000		$	(127,291,000	)	$	2,205,000			87,223,141	$	873,000	$	127,882,000	$	(124,249,000	)	$	4,506,000
Share-based compensation expense - stock options		—		—		103,000			—			103,000			—		—		193,000		—			193,000
Share-based compensation expense - restricted stock units		—		—		20,000			—			20,000			—		—		20,000		—			20,000

Issuance of common stock for vested restricted stock units		150,000		2,000		(2,000	)		—			—			-		-		-		—			—
Net loss		—		—		—			(760,000	)		(760,000	)		—		—		—		(811,000	)		(811,000	)
Balances at end of period (Unaudited)		88,023,141	$	881,000	$	128,738,000		$	(128,051,000	)	$	1,568,000			87,223,141	$	873,000	$	128,095,000	$	(125,060,000	)	$	3,908,000

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended
	April 30,
	2022			2021
Operating activities
Net loss	$	(2,258,000	)	$	(1,586,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		493,000			683,000
Depreciation and amortization		162,000			133,000
Gain on extinguishment of indebtedness		(239,000	)
Changes in operating assets and liabilities:
Accounts receivable		170,000			868,000
Inventories		31,000			(21,000	)
Prepaid expenses		7,000			(19,000	)
Accounts payable and accrued liabilities		(181,000	)		(813,000	)
Net cash used in operating activities		(1,815,000	)		(755,000	)
Investing activities
Purchases of property, plant and equipment		(64,000	)		(504,000	)
Net cash used in investing activities		(64,000	)		(504,000	)
Financing activities
Net proceeds from payroll protection program loan		—			239,000
Net cash provided by financing activities		—			239,000
Net decrease in cash, cash equivalents, and restricted cash		(1,879,000	)		(1,020,000	)
Cash, cash equivalents, and restricted cash at beginning of period		2,465,000			3,914,000
Cash, cash equivalents, and restricted cash at end of period	$	586,000		$	2,894,000

Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	511,000		$	2,819,000
Restricted cash	$	75,000		$	75,000
Total cash, cash equivalents and restricted cash	$	586,000		$	2,894,000

See accompanying notes.

PURE Bioscience, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

For the three and nine months ended April 30, 2022 and 2021

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended April 30, 2022 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2022. The July 31, 2021 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2021 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 28, 2021.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity and Going Concern

We have a history of recurring losses, and as of April 30, 2022 we have incurred a cumulative net loss of $128,051,000. During the nine months ended April 30, 2022, we recorded a net loss of $2,258,000 on recorded net revenue of $1,441,000. In addition, during the nine months ended April 30, 2022 we used $1,879,000 in operating and investing activities resulting in a cash balance of $511,000 as of April 30, 2022. Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended July 31, 2021, has also expressed substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern.

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

3. Significant Accounting Policies

Revenue Recognition

We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid.

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

A summary of our revenue by product type for the nine months ended April 30, 2022 and 2021 is as follows:

Summary of Revenue by Product


	April 30,
	2022		2021
PURE Hard Surface	$	1,158,000	$	2,815,000
SILVÉRION		251,000		26,000
Total	$	1,409,000	$	2,841,000

A summary of our revenue by product type for the three months ended April 30, 2022 and 2021 is as follows:


	April 30,
	2022		2021
PURE Hard Surface	$	352,000	$	556,000
SILVÉRION		145,000		—
Total	$	497,000	$	556,000

Variable Consideration

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Net Loss Per Share

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2022 and 2021, stock options, warrants and shares issuable under restricted stock unit awards of 7,391,625 and 10,358,765, respectively, have been excluded from the computation of diluted shares outstanding.

	April 30,
	2022		2021
Common stock options		6,179,125		8,018,500
Restricted stock units		1,212,500		2,012,500
Warrants		—		327,765
Total		7,391,625		10,358,765

Inventory

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Inventories consist of the following:

Schedule of Inventories


	April 30, 2022		July 31, 2021
Raw materials	$	17,000	$	17,000
Finished goods		284,000		315,000
Inventories	$	301,000	$	332,000

Share-Based Compensation

We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period.

We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.

Impairment of Long-Lived Assets

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and nine months ended April 30, 2022 and 2021, no impairment of long-lived assets was indicated or recorded.

Concentrations

Gross product sales. For the three months ended April 30, 2022, three individual customers accounted for 29%, 14% and 11% of our net product sales, respectively. For the nine months ended April 30, 2022, three customers accounted for 14%, 12% and 10% of our net product sales, respectively. For the three months ended April 30, 2021, three individual customers accounted for 25%, 12% and 11% of our net product sales. For the nine months ended April 30, 2021, two customers accounted for 18% and 10% of our net product sales, respectively.

Accounts receivable. As of April 30, 2022, we had accounts receivable from four customers that comprised of 15%, 14%, 12 and 11% of total accounts receivable, respectively. As of April 30, 2021, we had accounts receivable from three customers that comprised 22%, 15% and 13% of total accounts receivable, respectively.

Purchases. For the three months ended April 30, 2022, two vendors accounted for 26% and 12% of our purchases, respectively. For the nine months ended April 30, 2022, one vendor accounted for 21% of our purchases. For the three months ended April 30, 2021, two vendors accounted for 23% and 12% of our purchases, respectively. For the nine months ended April 30, 2021, one vendor accounted for 35% of our purchases.

Accounts payable. As of April 30, 2022, our largest vendor accounted for 25% of the total accounts payable. As of April 30, 2021, our largest three vendors accounted for 36%, 17% and 14% of the total trade accounts payable, respectively.

Segments

We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

4. Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivable. The standard will replace today’s “incurred loss” approach with an “expected loss” model , under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As small business filer, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 is not expected to have any impact on the Company’s consolidated financial statement presentation or disclosures.

Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

5. Debt

Receipt of CARES funding

In April 2021, we were funded $239,000 under the Payroll Protection Program (“PPP”) through California Bank and Trust. The PPP was established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. The amount of loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan.

During the nine months ended April 30, 2022, we applied and received loan forgiveness under the provisions of the CARES Act for the entire $239,000 loan. This amount was recorded as a gain on extinguishment of indebtedness on the Condensed Consolidated Statement of Operations during the nine months ended April 30, 2022.

6. Stockholders’ Equity

Restricted Stock Units

The Company issues restricted stock unit awards (“RSUs”) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term.

On October 4, 2018, the Board of Directors appointed Tom Myers as the Company’s Chief Operating Officer. In connection with Mr. Myers appointment, the Board agreed to grant him 500,000 RSUs upon the achievement by the Company of profitability for a fiscal quarter, after which such RSUs shall vest annually over the following three years. In May 2020, the 500,000 RSUs were formally granted to Mr. Myers due to the Company’s profitable April 30, 2020 fiscal quarter. During the nine months ended April 30, 2022 there were no Restricted Stock Units granted.

As of July 31, 2021, the Company had granted 2,012,500 RSU’s of which 1,679,167 had vested. As of July 31, 2021, 333,333 RSU’s with a fair value of $144,000, remained unvested. None of the shares vested under the RSUs had been issued as of July 31, 2021.

During the nine months ended April 30, 2022 and 2021, the Company recognized $62,000 of compensation cost relating to RSU’s previously granted to Mr. Tom Myers, the Company’s Chief Operating Officer, which are being amortized over their three year vesting term. As of April 30, 2022, there was $82,000 of unrecognized non-cash compensation cost related to the remaining 333,333 RSUs we expect to vest, which will be recognized over a weighted average period of 1.0 year.

During the nine months ended April 30, 2022, 800,000 RSUs were issued and delivered. Of the 1,212,500 RSUs outstanding as of April 30, 2022, 879,167 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.

A summary of our restricted stock unit activity and related data is as follows:

Schedule of Restricted Stock Activity

	Total RSU Shares			Vested and Issuable
Outstanding at July 31, 2021		2,012,500			1,679,167
Granted		—			—
Issued		(800,000	)		(800,000	)
Forfeited		—			—
Outstanding at April 30, 2022		1,212,500			879,167

Stock Option Plans

2007 Equity Incentive Plan

In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2022, there were approximately 1,552,000 shares available for issuance under the 2007 Plan.

2017 Equity Incentive Plan

In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2022, there were approximately 3,755,000 shares available for issuance under the 2017 Plan.

During the nine months ended April 30, 2022, we authorized the issuance of 170,000 stock options to new employees. The options have a fair value of $36,000 as determined by the Black Scholes option pricing model, vest between one and three years and carry a ten year term. During the nine months ended April 30, 2021, we authorized the issuance of 60,000 stock options to a consultant with a fair value of $48,000 as determined by the Black Scholes option pricing model. The options vest quarterly over one year and carry a five year term. There were no stock option grants during the three months ended April 30, 2022 and 2021.

A summary of our stock option activity is as follows:

Schedule of Stock Option Activity

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2021		8,644,125		$	0.76	$	124,000
Granted		170,000		$	0.29		2,000
Exercised		—		$	—		—
Expired		(2,635,000	)	$	1.05		—
Outstanding at April 30, 2022		6,179,125		$	0.62	$	—

The weighted-average remaining contractual term of options outstanding at April 30, 2022 was 6.64 years.

At April 30, 2022, options to purchase 5,466,625 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.64 and a weighted average remaining contractual term of 6.31 years. The total unrecognized compensation cost related to unvested stock option grants as of April 30, 2022 was approximately $150,000 and the weighted average period over which these grants are expected to vest is 0.83 years.

For the nine months ended April 30, 2022 share-based compensation expense for stock options that vested during the period was $431,000. For the nine months ended April 30, 2021 share-based compensation expense for stock options that vested during the period was $621,000.

We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

Schedule of Fair Value Assumptions

	Nine Months Ended April 30, 2022			Nine Months Ended April 30, 2021
Volatility		88.35.	%		104.93.	%
Risk-free interest rate		1.17	%		0.18	%
Dividend yield		0.0	%		0.0	%
Expected life		5.59 years			2.81 years

Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

7. Related Party Transactions

As of April 30, 2022 and April 30, 2021, accounts payable include $136,000 and $63,600 in board fees due to officers and directors, respectively.

8. Commitments and Contingencies

COVID-19

The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we previously benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We subsequently experienced an abatement in such demand and cannot assure you that demand will stabilize. Additionally, we are beginning to experience supply chain issues with our various plastic packaging configurations and citric acid. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.

The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references in this Item 2 and elsewhere in this Quarterly Report to “PURE,” “we”, “our,” “us” and the “Company” refer to PURE Bioscience, Inc., a Delaware corporation, and our wholly owned subsidiary, ETI H2O, Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements contained elsewhere in this Quarterly Report.

The discussion in this section contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “would” or “will” or the negative of these terms or other comparable terminology, but their absence does not mean that a statement is not forward-looking. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which could cause our actual results to differ from those projected in any forward-looking statements we make. Several risks and uncertainties we face are discussed in more detail under “Risk Factors” in Part II, Item 1A of this Quarterly Report or in the discussion and analysis below. You should, however, understand that it is not possible to predict or identify all risks and uncertainties and you should not consider the risks and uncertainties identified by us to be a complete set of all potential risks or uncertainties that could materially affect us. You should not place undue reliance on the forward-looking statements we make herein because some or all of them may turn out to be wrong. We undertake no obligation to update any of the forward-looking statements contained herein to reflect future events and developments, except as required by law. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are focused on developing and commercializing proprietary antimicrobial products that provide safe and cost-effective solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, we believe SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, non-causticity and the inability of bacteria to form a resistance to it.

We believe there is a significant market opportunity for our safe, non-toxic, non-caustic and effective SDC-based solutions. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid. In addition to our direct sales efforts with PURE Hard Surface and PURE Control, we market and sell our SDC-based products indirectly through third-party distributors supporting various industries.

Business Strategy

Our goal is to become a sustainable company by commercializing the SDC-based products we have developed with our proprietary technology platform. We are focused on delivering leading antimicrobial products that address food safety risks across the food industry supply chain. Key aspects of our business strategy include:

●

Expanding sales and distribution for our products into the food industry with a focus on a dual track of food safety market opportunities:

		●	*Hard Surface Disinfectant* - commercializing our current EPA registered PURE Hard Surface disinfectant and sanitizer for use in foodservice operations, food manufacturing and food transportation.

		●	*Direct Food Contact* - commercializing FDA approved PURE Control as a direct food contact processing aid for fresh produce; commercializing FDA approved PURE Control as a food processing and intervention aid for food processors treating raw poultry in pre and post on-line reprocessing.

	●	Continuing to grow and establish new strategic alliances to maximize the commercial potential of our technology platform;

	●	Continuing to partner with third parties who are seeking, or intend to seek, approvals to market SDC-based products in markets outside the U.S.

	●	Developing additional proprietary products and applications; and

	●	Protecting and enhancing our intellectual property.

In addition to our current products addressing food safety, we intend to leverage our technology platform through licensing and distribution collaborations in order to develop new products and enter into new markets that could potentially generate multiple sources of revenue.

Financial Overview

This financial overview provides a general description of our revenue and expenses.

Net Product Sales

We contract manufacture and sell SDC-based products for end use, and as a raw material for manufacturing use. We recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Any amounts received prior to satisfying revenue recognition criteria are recorded as deferred revenue. See “Critical Accounting Policies and Estimates – Revenue Recognition”.

Cost of Goods Sold

Cost of goods sold for product sales includes direct and indirect costs to manufacture products, including materials consumed, manufacturing overhead, shipping costs, salaries, benefits, reserved inventory, and related expenses of operations. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Selling, General and Administrative

Selling, general and administrative expense consists primarily of salaries and other related costs for personnel in business development, sales, finance, accounting, information technology, and executive functions. Other selling, general and administrative costs include product marketing, advertising, and trade show costs, as well as public relations and investor relations, facility costs, and legal, accounting and other professional fees.

Research and Development

Our research and development activities are focused on leveraging our technology platform to develop additional proprietary products and applications. Research and development expense consists primarily of personnel and related costs, product registration expenses, and third-party testing. We expense research and development costs as incurred.

Other Income (Expense)

We record interest income, interest expense, the change in derivative liabilities, as well as other non-operating transactions, as other income (expense) in our consolidated statements of operations.

COVID-19

Results of Operations

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our results of operations will be affected for the foreseeable future by several factors that may contribute to these periodic fluctuations, including fluctuations in the buying patterns of our current or potential customers for which we have no visibility, the mix of product sales including a change in the percentage of higher or lower margin formulations and packaging configurations of our products, the cost of product sales including component costs, our inability for any reason to be able to meet demand, the achievement and timing of research and development and regulatory milestones, unforeseen changes in expenses, including non-cash expenses such as the fair value of equity awards granted and the fair value change of derivative liabilities, the calculation of which includes several variable assumptions, and unforeseen manufacturing or supply issues, among other issues. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance. As of the date of this filing, we are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future.

Comparison of the Three Months Ended April 30, 2022 and 2021

Net Product Sales

Net product sales were $497,000 and $556,000 for the three months ended April 30, 2022 and 2021, respectively. The decrease of $59,000 was attributable to decreased sales across our distribution network servicing the food processing, transportation and janitorial industry. Our top three customers accounted for $269,000 of net product sales for the three months ended April 30, 2022.

For the three months ended April 30, 2022, three individual customers accounted for 29%, 14% and 11% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

For the three months ended April 30, 2021, three individual customers accounted for 25%, 12% and 11% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

During the three months ended April 30, 2022 and 2021, we recognized $27,000 and $5,000 in royalties from a nonexclusive third-party distributor, respectively.

Cost of Goods Sold

Cost of goods sold was $199,000 and $246,000 for the three months ended April 30, 2022 and 2021, respectively. The decrease of $47,000 was primarily attributable to decreased product sales.

Gross margin as a percentage of net product sales, or gross margin percentage, was 60% and 56% for the three months ended April 30, 2022 and 2021, respectively. The increase in gross margin percentage was primarily attributable to the sale of higher margin formulations and packaging configurations of our products during the quarter ended April 30, 2022 as compared with the prior period.

Selling, General and Administrative Expense

Selling, general and administrative expense was $977,000 and $1,036,000 for the three months ended April 30, 2022 and 2021, respectively. The decrease of $59,000 was primarily attributable to decreased personnel costs and facilities expenses. These decreases were partially offset by increased marketing, travel and professional service expense.

Share-based compensation expense, included in selling, general and administrative expense, was $123,000 and $213,000 for the three months ended April 30, 2022 and 2021, respectively. The decrease of $90,000 is primarily due to the prior year vesting of stock options and restricted stock units granted to employees, directors and consultants supporting our selling, general and administrative functions.

Research and Development Expense

Research and development expense, primarily consisting of third-party fees and personnel costs, was $107,000 and $89,000 for the three months ended April 30, 2022 and 2021, respectively. The increase of $18,000 was due to increased personnel costs.

Comparison of the Nine Months Ended April 30, 2022 and 2021

Net Product Sales

Net product sales were $1,409,000 and $2,841,000 for the nine months ended April 30, 2022 and 2021, respectively. During the prior year the Company experienced a significant increase in sales due to the onset of the COVID-19 pandemic. There was no such increase during the current period. As a result, our comparable nine month product revenue decreased by $1,432,000. The decrease was attributable to decreased sales across our distribution network servicing the food processing, transportation and janitorial industry. Our top five customers accounted for $739,000 of net product sales for the nine months ended April 30, 2022.

For the nine months ended April 30, 2022, three individual customers accounted for 14%, 12% and 10% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

For the nine months ended April 30, 2021, two individual customers accounted for 18% and 10% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

During the nine months ended April 30, 2022 and 2021, we recognized $32,000 and $227,000 in royalties from a nonexclusive third-party distributor, respectively.

Cost of Goods Sold

Cost of goods sold was $553,000 and $1,250,000 for the nine months ended April 30, 2022 and 2021, respectively. The decrease of $697,000 was primarily attributable to decreased product sales.

Gross margin as a percentage of net product sales, or gross margin percentage, was 61% and 56% for the nine months ended April 30, 2022 and 2021, respectively. The increase in gross margin percentage was primarily attributable to the sale of higher margin formulations and packaging configurations of our products during the nine months ended April 30, 2022, as compared with the prior period.

Selling, General and Administrative Expense

Selling, general and administrative expense was $3,127,000 and $3,136,000 for the nine months ended April 30, 2022 and 2021, respectively. The decrease of $9,000 was primarily attributable to decreased personnel costs and legal fees. These decreases were partially offset by increased professional service costs, travel and marketing expense and board fees.

Share-based compensation expense, included in selling, general and administrative expense, was $493,000 and $683,000 for the nine months ended April 30, 2022 and 2021, respectively. The decrease of $190,000 is primarily due to the prior year vesting of stock options and restricted stock units granted to employees, directors and consultants supporting our selling, general and administrative functions.

Research and Development Expense

Research and development expense was $255,000 and $265,000 for the nine months ended April 30, 2022 and 2021, respectively. The decrease of $10,000 was due to a reduction in third-party fees.

Other Income (Expense)

Liquidity and Capital Resources

As of April 30, 2022, we had $511,000 in cash and cash equivalents compared with $2,390,000 in cash and cash equivalents as of July 31, 2021. The net decrease in cash and cash equivalents was primarily attributable to the use of cash to fund our operations and investments in property, plant and equipment. Additionally, as of April 30, 2022, we had $550,000 of current liabilities, including $416,000 in accounts payable, compared with $970,000 of current liabilities, including $593,000 in accounts payable as of July 31, 2021. The net decrease in current liabilities was primarily due to trade payables due to our contract manufacture and the forgiveness of the PPP Loan discussed above.

We have a history of recurring losses, and as of April 30, 2022 we have incurred a cumulative net loss of $128,051,000. During the nine months ended April 30, 2022, we recorded a net loss of $2,258,000 on recorded net revenue of $1,441,000. In addition, during the nine months ended April 30, 2022 we used $1,879,000 in operating and investing activities resulting in a cash balance of $511,000 as of April 30, 2022. Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern.

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In addition, the condensed consolidated financial statements included in this Quarterly Report have been prepared and presented on a basis assuming we will continue as a going concern. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether. Our financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

We believe the following accounting policies and estimates are critical to aid you in understanding and evaluating our reported financial results.

Revenue Recognition

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

Variable Consideration

Share-Based Compensation

We grant equity-based awards under share-based compensation plans or stand-alone contracts. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

Impairment of Long-Lived Assets

Recent Accounting Pronouncements

See Note 4 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

Off Balance Sheet Arrangements

We do not have any off balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, and as provided in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As required by Rule 13a-15(b) under the Exchange Act, our management conducted an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing evaluation, our Principal Executive Officer and Principal Financial Officer concluded that as of the end of the period covered by this report our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that there were no changes in our internal controls over financial reporting during the nine months ended April 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II – Other Information

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and any adverse result in these or other matters may arise from time to time that could harm our business. We are not currently aware of any such legal proceedings or claims to which we or our wholly owned subsidiary is a party or of which any of our property is subject that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, including the risk factor included below, as well as the risk factors disclosed in Item 1A. to Part I of our Annual Report on Form 10-K for the fiscal year ended July 31, 2021, which we filed with the SEC on October 28, 2021 (the “Form 10-K”). Other than the risk factor included below, the risks and uncertainties described in “Item 1A — Risk Factors” of our Form 10-K have not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q, including the risk factor included below, or any of the risks disclosed in “Item 1A — Risk Factors” of our Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

Risks Related to Our Business and Industry

As a result of our historical lack of financial liquidity, we do not currently have sufficient working capital to fund our planned operations and may not be able to continue as a going concern.

Our capital requirements will depend on many factors, including, among others:

	●	the market acceptance of, and demand for, our products;

	●	the timing and costs of executing our sales and marketing strategies;

	●	our ability to successfully complete the in-plant validation trials requested by potential customers and our ability to convert these trials into customer orders for our products;

	●	the costs and time required to obtain the necessary regulatory approvals for our products, including the required USDA approvals:

	●	the extent to which we invest in new testing and product development, including in-plant optimization trials;

	●	the extent to which our customers continue to place product orders as expected and expand their existing use of our products;

	●	the cost and time to satisfy unique customer requirements regarding validation trials or to support the value proposition and benefits of our products;

	●	the timing of vendor payments and the collection of receivables, among other factors affecting our working capital;

	●	our ability to control the timing and amount of our operating expenses, including the costs to attract and retain personnel with the skills required to implement our business plan; and

	●	the costs to file, prosecute and defend our intellectual property rights.

The above factors, along with our history and near term forecast of incurring net losses and negative operating cash flows, raise substantial doubt about our ability to continue as a going concern. If we do not obtain additional capital from external sources, we will not have sufficient working capital to fund our planned operations or be able to continue as a going concern. We cannot assure you that additional financing will be available when needed or that, if available, we can obtain financing on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.

The currently evolving situation related to the COVID-19 pandemic could adversely affect our business, financial condition and results of operations.

The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

3.1		Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.1.1		Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.1.2		Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on May 19, 2021).

3.2		Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

3.2.1		Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2.1 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

31.1 *		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 *		Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 *		Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 *		Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101 *		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarterly period ended April 30, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at April 30, 2022 and July 31, 2021; (ii) Condensed Consolidated Statements of Operations for the three and nine months ended April 30, 2022 and 2021; (iii) Condensed Consolidated Statements of Stockholders’ equity for the three and nine months ended April 30, 2022 and 2021 ;(iv) Condensed Consolidated Statements of Cash Flows for the nine months ended April 30, 2022 and 2021; and (v) Notes to Condensed Consolidated Financial Statements.

104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith.

Signatures

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PURE BIOSCIENCE, INC.

Date: June 14, 2022	By:	/s/ TOM Y. LEE
		Tom Y. Lee, Chief Executive Officer (Principal Executive Officer)

Date: June 14, 2022	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott, Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Tom Y. Lee, Chief Executive Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 14, 2022	By:	/s/ Tom Y. Lee
		Tom Y. Lee
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark S. Elliott, Vice President, Finance and Principal Financial and Accounting Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 14, 2022	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott
		Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Pure Bioscience, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

	(i)	the accompanying report on Form 10-Q of the Company for the period ended April 30, 2022, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 14, 2022	By:	/s/ Tom Y. Lee
		Tom Y. Lee
		Chief Executive Officer
		(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Pure Bioscience, Inc. and will be retained by Pure Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pure Bioscience, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

	(i)	the accompanying report on Form 10-Q of the Company for the period ended April 30, 2022, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 14, 2022	By:	/s/ Mark S. Elliott
		Mark S. Elliott
		Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-101.SCH 6 pure-20220430.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Liquidity and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Revenue by Product (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Schedule of Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pure-20220430_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pure-20220430_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pure-20220430_lab.xml XBRL LABEL FILE Product and Service [Axis] Product [Member] Royalty [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] PURE Hard Surface [Member] SILVERION [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Individual Customer One [Member] Individual Customer Two [Member] Individual Customer Three [Member] Accounts Receivable [Member] Customer One [Member] Customer Two [Member] Customer Three [Member] Customer Four [Member] Purchases [Member] Vendor One [Member] Vendor Two [Member] Accounts Payable [Member] Vendor Three [Member] Antidilutive Securities [Axis] Common Stock Option [Member] Restricted Stock Units (RSUs) [Member] Warrant [Member] Credit Facility [Axis] California Bank and Trust [Member] Debt Instrument [Axis] Payroll Protection Program [Member] Award Type [Axis] Title of Individual [Axis] Mr. Myers [Member] Scenario [Axis] Vested and Issuable [Member] Plan Name [Axis] 2007 Equity Incentive Plan [Member] 2017 Equity Incentive Plan [Member] New Employees [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Total RSU Shares [Member] Board Fees Due to Officers and Directors [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Accounts receivable Inventories, net Restricted cash Prepaid expenses Total current assets Property, plant and equipment, net Patents, net Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued liabilities Loan payable Total current liabilities Commitments and contingencies Stockholders’ equity Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding Common stock, $0.01 par value: 150,000,000 shares authorized, 88,023,141 shares issued and outstanding at April 30, 2022, and 87,223,141 shares issued and outstanding at July 31, 2021 Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] Total revenue Cost of goods sold Gross profit Operating costs and expenses Selling, general and administrative Research and development Total operating costs and expenses Loss from operations Other income (expense) Interest expense, net Gain on extinguishment of indebtedness, net Total other income (expense) Net loss Basic and diluted net loss per share Shares used in computing basic and diluted net loss per share Beginning balance, shares Beginning Balance Share-based compensation expense - stock options Share-based compensation expense - restricted stock units Issuance of common stock upon the exercise of stock options, shares Issuance of common stock upon the exercise of stock options Issuance of common stock for vested restricted stock units, shares Issuance of common stock for vested restricted stock units Net loss Ending balance, shares Ending Balance Statement of Cash Flows [Abstract] Operating activities Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation Depreciation and amortization Gain on extinguishment of indebtedness Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses Accounts payable and accrued liabilities Net cash used in operating activities Investing activities Purchases of property, plant and equipment Net cash used in investing activities Financing activities Net proceeds from payroll protection program loan Net cash provided by financing activities Net decrease in cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Cash and cash equivalents Restricted cash EX-101.PRE 10 pure-20220430_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Apr. 30, 2022	Jun. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Apr. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--07-31
Entity File Number	001-14468
Entity Registrant Name	PURE Bioscience, Inc.
Entity Central Index Key	0001006028
Entity Tax Identification Number	33-0530289
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9669 Hermosa Avenue
Entity Address, City or Town	Rancho Cucamonga
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91730
City Area Code	(619)
Local Phone Number	596-8600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		88,023,141

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Current assets
Cash and cash equivalents	$ 511,000	$ 2,390,000
Accounts receivable	198,000	368,000
Inventories, net	301,000	332,000
Restricted cash	75,000	75,000
Prepaid expenses	25,000	32,000
Total current assets	1,110,000	3,197,000
Property, plant and equipment, net	697,000	740,000
Patents, net	311,000	366,000
Total assets	2,118,000	4,303,000
Current liabilities
Accounts payable	416,000	593,000
Accrued liabilities	134,000	138,000
Loan payable		239,000
Total current liabilities	550,000	970,000
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 150,000,000 shares authorized, 88,023,141 shares issued and outstanding at April 30, 2022, and 87,223,141 shares issued and outstanding at July 31, 2021	881,000	873,000
Additional paid-in capital	128,738,000	128,253,000
Accumulated deficit	(128,051,000)	(125,793,000)
Total stockholders’ equity	1,568,000	3,333,000
Total liabilities and stockholders’ equity	$ 2,118,000	$ 4,303,000

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 30, 2022	Jul. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	88,023,141	87,223,141
Common stock, shares outstanding	88,023,141	87,223,141

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Total revenue	$ 524,000	$ 561,000	$ 1,441,000	$ 3,068,000
Cost of goods sold	199,000	246,000	553,000	1,250,000
Gross profit	325,000	315,000	888,000	1,818,000
Operating costs and expenses
Selling, general and administrative	977,000	1,036,000	3,127,000	3,136,000
Research and development	107,000	89,000	255,000	265,000
Total operating costs and expenses	1,084,000	1,125,000	3,382,000	3,401,000
Loss from operations	(759,000)	(810,000)	(2,494,000)	(1,583,000)
Other income (expense)
Interest expense, net	(1,000)	(1,000)	(3,000)	(3,000)
Gain on extinguishment of indebtedness, net			239,000
Total other income (expense)	(1,000)	(1,000)	236,000	(3,000)
Net loss	$ (760,000)	$ (811,000)	$ (2,258,000)	$ (1,586,000)
Basic and diluted net loss per share	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)
Shares used in computing basic and diluted net loss per share	87,925,388	87,223,141	87,741,639	87,157,857
Product [Member]
Total revenue	$ 497,000	$ 556,000	$ 1,409,000	$ 2,841,000
Royalty [Member]
Total revenue	$ 27,000	$ 5,000	$ 32,000	$ 227,000

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, shares at Jul. 31, 2020	87,072,951
Beginning Balance at Jul. 31, 2020	$ 871,000	$ 127,414,000	$ (123,474,000)	$ 4,811,000
Share-based compensation expense - stock options		621,000		621,000
Share-based compensation expense - restricted stock units		62,000		62,000
Issuance of common stock upon the exercise of stock options, shares	150,190
Issuance of common stock upon the exercise of stock options	$ 2,000	(2,000)
Issuance of common stock for vested restricted stock units, shares
Issuance of common stock for vested restricted stock units
Net loss			(1,586,000)	(1,586,000)
Ending balance, shares at Apr. 30, 2021	87,223,141
Ending Balance at Apr. 30, 2021	$ 873,000	128,095,000	(125,060,000)	3,908,000
Beginning balance, shares at Jan. 31, 2021	87,223,141
Beginning Balance at Jan. 31, 2021	$ 873,000	127,882,000	(124,249,000)	4,506,000
Share-based compensation expense - stock options		193,000		193,000
Share-based compensation expense - restricted stock units		20,000		20,000
Issuance of common stock for vested restricted stock units, shares
Issuance of common stock for vested restricted stock units
Net loss			(811,000)	(811,000)
Ending balance, shares at Apr. 30, 2021	87,223,141
Ending Balance at Apr. 30, 2021	$ 873,000	128,095,000	(125,060,000)	3,908,000
Beginning balance, shares at Jul. 31, 2021	87,223,141
Beginning Balance at Jul. 31, 2021	$ 873,000	128,253,000	(125,793,000)	3,333,000
Share-based compensation expense - stock options		431,000		431,000
Share-based compensation expense - restricted stock units		62,000		62,000
Issuance of common stock upon the exercise of stock options, shares
Issuance of common stock upon the exercise of stock options
Issuance of common stock for vested restricted stock units, shares	800,000
Issuance of common stock for vested restricted stock units	$ 8,000	(8,000)
Net loss			(2,258,000)	(2,258,000)
Ending balance, shares at Apr. 30, 2022	88,023,141
Ending Balance at Apr. 30, 2022	$ 881,000	128,738,000	(128,051,000)	1,568,000
Beginning balance, shares at Jan. 31, 2022	87,873,141
Beginning Balance at Jan. 31, 2022	$ 879,000	128,617,000	(127,291,000)	2,205,000
Share-based compensation expense - stock options		103,000		103,000
Share-based compensation expense - restricted stock units		20,000		20,000
Issuance of common stock for vested restricted stock units, shares	150,000
Issuance of common stock for vested restricted stock units	$ 2,000	(2,000)
Net loss			(760,000)	(760,000)
Ending balance, shares at Apr. 30, 2022	88,023,141
Ending Balance at Apr. 30, 2022	$ 881,000	$ 128,738,000	$ (128,051,000)	$ 1,568,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Operating activities
Net loss	$ (760,000)	$ (811,000)	$ (2,258,000)	$ (1,586,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation			493,000	683,000
Depreciation and amortization			162,000	133,000
Gain on extinguishment of indebtedness			(239,000)
Changes in operating assets and liabilities:
Accounts receivable			170,000	868,000
Inventories			31,000	(21,000)
Prepaid expenses			7,000	(19,000)
Accounts payable and accrued liabilities			(181,000)	(813,000)
Net cash used in operating activities			(1,815,000)	(755,000)
Investing activities
Purchases of property, plant and equipment			(64,000)	(504,000)
Net cash used in investing activities			(64,000)	(504,000)
Financing activities
Net proceeds from payroll protection program loan				239,000
Net cash provided by financing activities				239,000
Net decrease in cash, cash equivalents, and restricted cash			(1,879,000)	(1,020,000)
Cash, cash equivalents, and restricted cash at beginning of period			2,465,000	3,914,000
Cash, cash equivalents, and restricted cash at end of period	586,000	2,894,000	586,000	2,894,000
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	511,000	2,819,000	511,000	2,819,000
Restricted cash	75,000	75,000	75,000	75,000
Total cash, cash equivalents and restricted cash	$ 586,000	$ 2,894,000	$ 586,000	$ 2,894,000

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Apr. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1. Basis of Presentation

XML 18 R8.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern

9 Months Ended

Apr. 30, 2022

Liquidity And Going Concern

Liquidity and Going Concern

2. Liquidity and Going Concern

XML 19 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Apr. 30, 2022

Accounting Policies [Abstract]

Significant Accounting Policies

3. Significant Accounting Policies

Revenue Recognition

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

A summary of our revenue by product type for the nine months ended April 30, 2022 and 2021 is as follows:

Summary of Revenue by Product


	April 30,
	2022		2021
PURE Hard Surface	$	1,158,000	$	2,815,000
SILVÉRION		251,000		26,000
Total	$	1,409,000	$	2,841,000

A summary of our revenue by product type for the three months ended April 30, 2022 and 2021 is as follows:


	April 30,
	2022		2021
PURE Hard Surface	$	352,000	$	556,000
SILVÉRION		145,000		—
Total	$	497,000	$	556,000

Variable Consideration

Use of Estimates

Net Loss Per Share

	April 30,
	2022		2021
Common stock options		6,179,125		8,018,500
Restricted stock units		1,212,500		2,012,500
Warrants		—		327,765
Total		7,391,625		10,358,765

Inventory

Inventories consist of the following:

Schedule of Inventories


	April 30, 2022		July 31, 2021
Raw materials	$	17,000	$	17,000
Finished goods		284,000		315,000
Inventories	$	301,000	$	332,000

Share-Based Compensation

Impairment of Long-Lived Assets

Concentrations

Segments

XML 20 R10.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Apr. 30, 2022

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

4. Recent Accounting Pronouncements

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI https://asc.fasb.org/topic&trid=2122394

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Debt

9 Months Ended

Apr. 30, 2022

Debt Disclosure [Abstract]

Debt

5. Debt

Receipt of CARES funding

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity

9 Months Ended

Apr. 30, 2022

Equity [Abstract]

Stockholders’ Equity

6. Stockholders’ Equity

Restricted Stock Units

A summary of our restricted stock unit activity and related data is as follows:

Schedule of Restricted Stock Activity

	Total RSU Shares			Vested and Issuable
Outstanding at July 31, 2021		2,012,500			1,679,167
Granted		—			—
Issued		(800,000	)		(800,000	)
Forfeited		—			—
Outstanding at April 30, 2022		1,212,500			879,167

Stock Option Plans

2007 Equity Incentive Plan

2017 Equity Incentive Plan

A summary of our stock option activity is as follows:

Schedule of Stock Option Activity

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2021		8,644,125		$	0.76	$	124,000
Granted		170,000		$	0.29		2,000
Exercised		—		$	—		—
Expired		(2,635,000	)	$	1.05		—
Outstanding at April 30, 2022		6,179,125		$	0.62	$	—

The weighted-average remaining contractual term of options outstanding at April 30, 2022 was 6.64 years.

Schedule of Fair Value Assumptions

	Nine Months Ended April 30, 2022			Nine Months Ended April 30, 2021
Volatility		88.35.	%		104.93.	%
Risk-free interest rate		1.17	%		0.18	%
Dividend yield		0.0	%		0.0	%
Expected life		5.59 years			2.81 years

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Apr. 30, 2022

Related Party Transactions

7. Related Party Transactions

As of April 30, 2022 and April 30, 2021, accounts payable include $136,000 and $63,600 in board fees due to officers and directors, respectively.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Apr. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

COVID-19

XML 25 R15.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Apr. 30, 2022

Accounting Policies [Abstract]

Revenue Recognition

Revenue Recognition

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

A summary of our revenue by product type for the nine months ended April 30, 2022 and 2021 is as follows:

Summary of Revenue by Product


	April 30,
	2022		2021
PURE Hard Surface	$	1,158,000	$	2,815,000
SILVÉRION		251,000		26,000
Total	$	1,409,000	$	2,841,000

A summary of our revenue by product type for the three months ended April 30, 2022 and 2021 is as follows:


	April 30,
	2022		2021
PURE Hard Surface	$	352,000	$	556,000
SILVÉRION		145,000		—
Total	$	497,000	$	556,000

Variable Consideration

Use of Estimates

Use of Estimates

Net Loss Per Share

Net Loss Per Share

	April 30,
	2022		2021
Common stock options		6,179,125		8,018,500
Restricted stock units		1,212,500		2,012,500
Warrants		—		327,765
Total		7,391,625		10,358,765

Inventory

Inventory

Inventories consist of the following:

Schedule of Inventories


	April 30, 2022		July 31, 2021
Raw materials	$	17,000	$	17,000
Finished goods		284,000		315,000
Inventories	$	301,000	$	332,000

Share-Based Compensation

Share-Based Compensation

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Concentrations

Concentrations

Segments

Segments

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Apr. 30, 2022

Accounting Policies [Abstract]

Summary of Revenue by Product

A summary of our revenue by product type for the nine months ended April 30, 2022 and 2021 is as follows:

Summary of Revenue by Product


	April 30,
	2022		2021
PURE Hard Surface	$	1,158,000	$	2,815,000
SILVÉRION		251,000		26,000
Total	$	1,409,000	$	2,841,000

A summary of our revenue by product type for the three months ended April 30, 2022 and 2021 is as follows:


	April 30,
	2022		2021
PURE Hard Surface	$	352,000	$	556,000
SILVÉRION		145,000		—
Total	$	497,000	$	556,000

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

	April 30,
	2022		2021
Common stock options		6,179,125		8,018,500
Restricted stock units		1,212,500		2,012,500
Warrants		—		327,765
Total		7,391,625		10,358,765

Schedule of Inventories

Inventories consist of the following:

Schedule of Inventories


	April 30, 2022		July 31, 2021
Raw materials	$	17,000	$	17,000
Finished goods		284,000		315,000
Inventories	$	301,000	$	332,000

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Tables)

9 Months Ended

Apr. 30, 2022

Equity [Abstract]

Schedule of Restricted Stock Activity

A summary of our restricted stock unit activity and related data is as follows:

Schedule of Restricted Stock Activity

	Total RSU Shares			Vested and Issuable
Outstanding at July 31, 2021		2,012,500			1,679,167
Granted		—			—
Issued		(800,000	)		(800,000	)
Forfeited		—			—
Outstanding at April 30, 2022		1,212,500			879,167

Schedule of Stock Option Activity

A summary of our stock option activity is as follows:

Schedule of Stock Option Activity

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2021		8,644,125		$	0.76	$	124,000
Granted		170,000		$	0.29		2,000
Exercised		—		$	—		—
Expired		(2,635,000	)	$	1.05		—
Outstanding at April 30, 2022		6,179,125		$	0.62	$	—

Schedule of Fair Value Assumptions

	Nine Months Ended April 30, 2022			Nine Months Ended April 30, 2021
Volatility		88.35.	%		104.93.	%
Risk-free interest rate		1.17	%		0.18	%
Dividend yield		0.0	%		0.0	%
Expected life		5.59 years			2.81 years

XML 28 R18.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021	Jul. 31, 2021
Liquidity And Going Concern
Cumulative net loss	$ 128,051,000		$ 128,051,000		$ 125,793,000
Net loss	760,000	$ 811,000	2,258,000	$ 1,586,000
Revenue	524,000	561,000	1,441,000	3,068,000
Net cash provided by (used) in operating and investing activities			1,879,000
Cash and cash equivalents	$ 511,000	$ 2,819,000	$ 511,000	$ 2,819,000	$ 2,390,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Revenue by Product (Details) - USD ($)	3 Months Ended		9 Months Ended
Summary of Revenue by Product (Details) - USD ($)	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Product Information [Line Items]
Total	$ 497,000	$ 556,000	$ 1,409,000	$ 2,841,000
PURE Hard Surface [Member]
Product Information [Line Items]
Total	352,000	556,000	1,158,000	2,815,000
SILVERION [Member]
Product Information [Line Items]
Total	$ 145,000		$ 251,000	$ 26,000

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	7,391,625	10,358,765
Common Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	6,179,125	8,018,500
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	1,212,500	2,012,500
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities		327,765

XML 31 R21.htm IDEA: XBRL DOCUMENT

Schedule of Inventories (Details) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Accounting Policies [Abstract]
Raw materials	$ 17,000	$ 17,000
Finished goods	284,000	315,000
Inventories	$ 301,000	$ 332,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative)	3 Months Ended		9 Months Ended
Significant Accounting Policies (Details Narrative)	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022 shares	Apr. 30, 2021 Segments shares
Product Information [Line Items]
Dilutive common share \| shares			7,391,625	10,358,765
Number of operating segments \| Segments				1
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Individual Customer One [Member]
Product Information [Line Items]
Concentration risk percentage	29.00%	25.00%	14.00%	18.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Individual Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage	14.00%	12.00%	12.00%	10.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Individual Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage	11.00%	11.00%	10.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			15.00%	22.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			14.00%	15.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage			12.00%	13.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Four [Member]
Product Information [Line Items]
Concentration risk percentage			11.00%
Customer Concentration Risk [Member] \| Purchases [Member] \| Vendor One [Member]
Product Information [Line Items]
Concentration risk percentage	26.00%	23.00%	21.00%	35.00%
Customer Concentration Risk [Member] \| Purchases [Member] \| Vendor Two [Member]
Product Information [Line Items]
Concentration risk percentage	12.00%	12.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor One [Member]
Product Information [Line Items]
Concentration risk percentage			25.00%	36.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor Two [Member]
Product Information [Line Items]
Concentration risk percentage				17.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor Three [Member]
Product Information [Line Items]
Concentration risk percentage				14.00%

XML 33 R23.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - California Bank and Trust [Member] - Payroll Protection Program [Member] - USD ($)		1 Months Ended	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2021	Apr. 30, 2022
Line of Credit Facility [Line Items]
Net proceeds from payroll protection program loan		$ 239,000	$ 239,000
Debt description		The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs.
Debt instrument interest percentage	1.00%	1.00%
Debt instrument term	2 years

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 34 R24.htm IDEA: XBRL DOCUMENT

Schedule of Restricted Stock Activity (Details)	9 Months Ended
Schedule of Restricted Stock Activity (Details)	Apr. 30, 2022 shares
Total RSU Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, Beginning balance	2,012,500
Granted
Issued	(800,000)
Forfeited
Outstanding, Ending balance	1,212,500
Vested and Issuable [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, Beginning balance	1,679,167
Granted
Issued	(800,000)
Forfeited
Outstanding, Ending balance	879,167

XML 35 R25.htm IDEA: XBRL DOCUMENT

Schedule of Stock Option Activity (Details) - 2017 Equity Incentive Plan [Member]	9 Months Ended
	Apr. 30, 2022 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options Outstanding Shares, Beginning Balance \| shares	8,644,125
Weighted- Average Exercise Price Outstanding, Beginning Balance \| $ / shares	$ 0.76
Aggregate Intrinsic Value Outstanding, Beginning Balance \| $	$ 124,000
Options Granted, Shares \| shares	170,000
Weighted- Average Exercise Price Granted \| $ / shares	$ 0.29
Aggregate Intrinsic Value Outstanding, Granted \| $	$ 2,000
Options Exercised, Shares \| shares
Weighted- Average Exercise Price Exercised \| $ / shares
Options Cancelled, Shares \| shares	(2,635,000)
Weighted- Average Exercise Price Cancelled \| $ / shares	$ 1.05
Options Outstanding Shares, Ending Balance \| shares	6,179,125
Weighted- Average Exercise Price Outstanding, Ending Balance \| $ / shares	$ 0.62
Aggregate Intrinsic Value Outstanding, Ending Balance \| $

XML 36 R26.htm IDEA: XBRL DOCUMENT

Schedule of Fair Value Assumptions (Details)	9 Months Ended
Schedule of Fair Value Assumptions (Details)	Apr. 30, 2022	Apr. 30, 2021
Equity [Abstract]
Volatility	88.35%	104.93%
Risk-free interest rate	1.17%	0.18%
Dividend yield	0.00%	0.00%
Expected life	5 years 7 months 2 days	2 years 9 months 21 days

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Details Narrative) - USD ($)		1 Months Ended				9 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Oct. 04, 2018	Jul. 31, 2021	Jan. 31, 2021	May 31, 2020	Feb. 29, 2016	Apr. 30, 2022	Apr. 30, 2021	Jan. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation						$ 431,000	$ 621,000
Unrecognized non-cash compensation costs						$ 150,000
Weighted average contractual term						6 years 7 months 20 days
Options issued to purchase common stock exercisable						5,466,625
Weighted average exercise price						$ 0.64
Weighted average contractual term						6 years 3 months 21 days
Weighted average contractual term grants						9 months 29 days
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation, vesting period						1 year
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation, vesting period						3 years
2007 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation, vesting period					10 years
Common stock shares increase under the plan					4,000,000
Share-based compensation, expiration date					Feb. 04, 2026
Number of shares available for issuance under the plan						1,552,000
2017 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation, vesting period			10 years
Common stock shares increase under the plan			5,000,000
Number of shares available for issuance under the plan						3,755,000
New Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation, vesting period						10 years	5 years
Number of stock option authorized for issuance						170,000	60,000
Fair value of stock option						$ 36,000
Number of stock option authorized fair value							$ 48,000
New Employees [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation, vesting period							1 year
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units, vested		1,679,167				800,000
Restricted stock options, granted		2,012,500
Number of restricted stock shares		333,333						333,333
Number of shares authorized remained unvested		$ 144,000
Share-based compensation						$ 62,000	$ 62,000
Share-based compensation, vesting period						3 years
Unrecognized non-cash compensation costs						$ 82,000
Weighted average period, restricted stock						1 year
Restricted Stock Units (RSUs) [Member] \| Vested and Issuable [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units, vested						1,212,500
Number of units, vested and issuable						879,167
Restricted Stock Units (RSUs) [Member] \| Mr. Myers [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units, vested	500,000			500,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Apr. 30, 2022	Jul. 31, 2021	Apr. 30, 2021
Accounts payable	$ 416,000	$ 593,000
Board Fees Due to Officers and Directors [Member]
Accounts payable	$ 136,000		$ 63,600

XML 39 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001006028 2021-08-01 2022-04-30 0001006028 2022-06-14 0001006028 2022-04-30 0001006028 2021-07-31 0001006028 us-gaap:ProductMember 2021-08-01 2022-04-30 0001006028 us-gaap:ProductMember 2020-08-01 2021-04-30 0001006028 us-gaap:ProductMember 2022-02-01 2022-04-30 0001006028 us-gaap:ProductMember 2021-02-01 2021-04-30 0001006028 us-gaap:RoyaltyMember 2021-08-01 2022-04-30 0001006028 us-gaap:RoyaltyMember 2020-08-01 2021-04-30 0001006028 us-gaap:RoyaltyMember 2022-02-01 2022-04-30 0001006028 us-gaap:RoyaltyMember 2021-02-01 2021-04-30 0001006028 2020-08-01 2021-04-30 0001006028 2022-02-01 2022-04-30 0001006028 2021-02-01 2021-04-30 0001006028 us-gaap:CommonStockMember 2021-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001006028 us-gaap:RetainedEarningsMember 2021-07-31 0001006028 us-gaap:CommonStockMember 2020-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001006028 us-gaap:RetainedEarningsMember 2020-07-31 0001006028 2020-07-31 0001006028 us-gaap:CommonStockMember 2022-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001006028 us-gaap:RetainedEarningsMember 2022-01-31 0001006028 2022-01-31 0001006028 us-gaap:CommonStockMember 2021-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001006028 us-gaap:RetainedEarningsMember 2021-01-31 0001006028 2021-01-31 0001006028 us-gaap:CommonStockMember 2021-08-01 2022-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-08-01 2022-04-30 0001006028 us-gaap:RetainedEarningsMember 2021-08-01 2022-04-30 0001006028 us-gaap:CommonStockMember 2020-08-01 2021-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2021-04-30 0001006028 us-gaap:RetainedEarningsMember 2020-08-01 2021-04-30 0001006028 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0001006028 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0001006028 us-gaap:CommonStockMember 2021-02-01 2021-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-04-30 0001006028 us-gaap:RetainedEarningsMember 2021-02-01 2021-04-30 0001006028 us-gaap:CommonStockMember 2022-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001006028 us-gaap:RetainedEarningsMember 2022-04-30 0001006028 us-gaap:CommonStockMember 2021-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001006028 us-gaap:RetainedEarningsMember 2021-04-30 0001006028 2021-04-30 0001006028 PURE:PureHardSurfaceMember 2021-08-01 2022-04-30 0001006028 PURE:PureHardSurfaceMember 2020-08-01 2021-04-30 0001006028 PURE:SilVerionMember 2021-08-01 2022-04-30 0001006028 PURE:SilVerionMember 2020-08-01 2021-04-30 0001006028 PURE:PureHardSurfaceMember 2022-02-01 2022-04-30 0001006028 PURE:PureHardSurfaceMember 2021-02-01 2021-04-30 0001006028 PURE:SilVerionMember 2022-02-01 2022-04-30 0001006028 PURE:SilVerionMember 2021-02-01 2021-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:IndividualCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:IndividualCustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:IndividualCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:IndividualCustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-02-01 2021-04-30 0001006028 PURE:IndividualCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-02-01 2021-04-30 0001006028 PURE:IndividualCustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-02-01 2021-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:IndividualCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:VendorOneMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:VendorTwoMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:VendorOneMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:VendorOneMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2021-02-01 2021-04-30 0001006028 PURE:VendorTwoMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2021-02-01 2021-04-30 0001006028 PURE:VendorOneMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:VendorOneMember PURE:AccountsPayablesMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:VendorOneMember PURE:AccountsPayablesMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:VendorTwoMember PURE:AccountsPayablesMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:VendorThreeMember PURE:AccountsPayablesMember us-gaap:CustomerConcentrationRiskMember 2020-08-01 2021-04-30 0001006028 PURE:CommonStockOptionMember 2021-08-01 2022-04-30 0001006028 PURE:CommonStockOptionMember 2020-08-01 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-08-01 2022-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2020-08-01 2021-04-30 0001006028 us-gaap:WarrantMember 2021-08-01 2022-04-30 0001006028 us-gaap:WarrantMember 2020-08-01 2021-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PayrollProtectionProgramMember 2021-04-01 2021-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PayrollProtectionProgramMember 2021-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PayrollProtectionProgramMember 2021-04-29 2021-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PayrollProtectionProgramMember 2021-08-01 2022-04-30 0001006028 PURE:MrMyersMember us-gaap:RestrictedStockUnitsRSUMember 2018-10-01 2018-10-04 0001006028 PURE:MrMyersMember us-gaap:RestrictedStockUnitsRSUMember 2020-05-01 2020-05-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-07-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-07-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-08-01 2022-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2020-08-01 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2022-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2022-01-31 0001006028 PURE:VestedAndIssuableMember us-gaap:RestrictedStockUnitsRSUMember 2021-08-01 2022-04-30 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2016-02-01 2016-02-29 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2022-04-30 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2021-01-01 2021-01-31 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2022-04-30 0001006028 PURE:NewEmployeesMember 2022-04-30 0001006028 PURE:NewEmployeesMember 2021-08-01 2022-04-30 0001006028 srt:MinimumMember 2021-08-01 2022-04-30 0001006028 srt:MaximumMember 2021-08-01 2022-04-30 0001006028 PURE:NewEmployeesMember 2021-04-30 0001006028 srt:MinimumMember PURE:NewEmployeesMember 2020-08-01 2021-04-30 0001006028 PURE:NewEmployeesMember 2020-08-01 2021-04-30 0001006028 PURE:TotalRSUSharesMember 2021-07-31 0001006028 PURE:VestedAndIssuableMember 2021-07-31 0001006028 PURE:TotalRSUSharesMember 2021-08-01 2022-04-30 0001006028 PURE:VestedAndIssuableMember 2021-08-01 2022-04-30 0001006028 PURE:TotalRSUSharesMember 2022-04-30 0001006028 PURE:VestedAndIssuableMember 2022-04-30 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2021-07-31 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2021-08-01 2022-04-30 0001006028 PURE:BoardFeesDuetoOfficersAndDirectorsMember 2022-04-30 0001006028 PURE:BoardFeesDuetoOfficersAndDirectorsMember 2021-04-30 iso4217:USD shares iso4217:USD shares pure PURE:Segments 0001006028 false Q3 2022 --07-31

P1Y

10-Q true 2022-04-30 false 001-14468 PURE Bioscience, Inc. DE 33-0530289 9669 Hermosa Avenue Rancho Cucamonga CA 91730 (619) 596-8600 Yes Yes Non-accelerated Filer true false false 88023141

511000

2390000

198000

368000

301000

332000

75000

25000

32000

1110000

3197000

697000

740000

311000

366000

2118000

4303000

416000

593000

134000

138000

239000

550000

970000

0.01

5000000

0.01

150000000

88023141

87223141

881000

873000

128738000

128253000

-128051000

-125793000

1568000

3333000

2118000

4303000

1409000

2841000

497000

556000

32000

227000

27000

5000

1441000

3068000

524000

561000

553000

1250000

199000

246000

888000

1818000

325000

315000

3127000

3136000

977000

1036000

255000

265000

107000

89000

3382000

3401000

1084000

1125000

-2494000

-1583000

-759000

-810000

3000

1000

239000

236000

-3000

-1000

-2258000

-1586000

-760000

-811000

-0.03

-0.02

-0.01

87741639

87157857

87925388

87223141

873000

128253000

-125793000

3333000

87072951

871000

127414000

-123474000

4811000

431000

621000

62000

150190

2000

-2000

800000 8000 -8000

-2258000

-1586000

88023141

881000

128738000

-128051000

1568000

87223141

873000

128095000

-125060000

3908000

87873141

879000

128617000

-127291000

2205000

87223141

873000

127882000

-124249000

4506000

103000

193000

20000

150000 2000 -2000

-760000

-811000

88023141

881000

128738000

-128051000

1568000

87223141

873000

128095000

-125060000

3908000

-2258000

-1586000

493000

683000

162000

133000

239000

-170000

-868000

-31000

21000

-7000

19000

-181000

-813000

-1815000

-755000

64000

504000

-64000

-504000

239000

-1879000

-1020000

2465000

3914000

586000

2894000

511000

2819000

75000

586000

2894000

<p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqhtFb3KRxL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended April 30, 2022 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2022. The July 31, 2021 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2021 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 28, 2021. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity and Going Concern We have a history of recurring losses, and as of April 30, 2022 we have incurred a cumulative net loss of $128,051,000. During the nine months ended April 30, 2022, we recorded a net loss of $2,258,000 on recorded net revenue of $1,441,000. In addition, during the nine months ended April 30, 2022 we used $1,879,000 in operating and investing activities resulting in a cash balance of $511,000 as of April 30, 2022. Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended July 31, 2021, has also expressed substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern. Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources. Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

-128051000

-2258000

1441000

1879000

511000

3. Significant Accounting Policies Revenue Recognition We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the contract with the customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">4.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocate the transaction price to the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">5.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognize revenue when (or as) each performance obligation is satisfied</td></tr> </table> Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid. Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of our revenue by product type for the nine months ended April 30, 2022 and 2021 is as follows: Summary of Revenue by Product <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_497_20210801__20220430_zryAucnhKPSk" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_498_20200801__20210430_zYNSzJdbi5bi" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PureHardSurfaceMember_zfHhoAyWDlIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,158,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,815,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zSmOP8R9wyD4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zeOyId52Xmp" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,409,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,841,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of our revenue by product type for the three months ended April 30, 2022 and 2021 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_492_20220201__20220430_zpk6cieogKNj" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49E_20210201__20210430_z8fhpFPynuy5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PureHardSurfaceMember_zRoYevgYx9Dh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">352,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">556,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zTGKxuI8CK56" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_zWkZHIWrojUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">497,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">556,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2022 and 2021, stock options, warrants and shares issuable under restricted stock unit awards of 7,391,625 and 10,358,765, respectively, have been excluded from the computation of diluted shares outstanding. <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zErokQH9oVy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_zZZYwAAKoJhk" style="width: 16%; text-align: right" title="Common stock option">6,179,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_z7HSIgv9Vva3" style="width: 16%; text-align: right" title="Common stock option">8,018,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zfkPLTeCJBVg" style="text-align: right" title="Restricted stock units">1,212,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqLK47p9bgce" style="text-align: right" title="Restricted stock units">2,012,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zadBSWGWzAeb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zCsi23BCZZK1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants">327,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430_zEBs2LOF8bo" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti dilutive securities">7,391,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430_zcS0GIVFx3xe" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti dilutive securities">10,358,765</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49E_20220430_ziUTxo0YKwX5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_495_20210731_zhg2WVEskwv5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">April 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">July 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_maINzkyC_zx2rDRkzGWok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoods_iI_maINzkyC_zpTamjVbO7Qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">284,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">315,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtINzkyC_z2576UJXdwL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">332,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Share-Based Compensation We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zb97jCIFF7ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and nine months ended April 30, 2022 and 2021, no impairment of long-lived assets was indicated or recorded. Concentrations Gross product sales. For the three months ended April 30, 2022, three individual customers accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zR0bKyUlPGA7" title="Concentration risk percentage">29%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_z3aEqfhAt8Yb" title="Concentration risk percentage">14% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_zbNjgd9gfbL1" title="Concentration risk percentage">11% of our net product sales, respectively. For the nine months ended April 30, 2022, three customers accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zibojbdOz1E" title="Concentration risk percentage">14%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_zQcl6Va4scFl" title="Concentration risk percentage">12% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_zxuuzkUA70Y5" title="Concentration risk percentage">10% of our net product sales, respectively. For the three months ended April 30, 2021, three individual customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_z0vMCVLWkFXl" title="Concentration risk percentage">25%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_z5fa1WCqNqZh" title="Concentration risk percentage">12% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_z7PhsZXYl3Ag" title="Concentration risk percentage">11% of our net product sales. For the nine months ended April 30, 2021, two customers accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zr0nL5ggqsM7" title="Concentration risk percentage">18% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_zT57cp9vNsS9" title="Concentration risk percentage">10% of our net product sales, respectively. Accounts receivable. As of April 30, 2022, we had accounts receivable from four customers that comprised of <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zouATTQGH5Ge" title="Concentration risk percentage">15%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zmfvLO5jw741" title="Concentration risk percentage">14%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zcUWXVfTS24k" title="Concentration risk percentage">12 and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zo63j0eHXF05" title="Concentration risk percentage">11% of total accounts receivable, respectively. As of April 30, 2021, we had accounts receivable from three customers that comprised <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zpofD4fL15Z9" title="Concentration risk percentage">22%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zOXIFMlofZE2" title="Concentration risk percentage">15% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zeAhqksAk2Bh" title="Concentration risk percentage">13% of total accounts receivable, respectively. Purchases. For the three months ended April 30, 2022, two vendors accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zd1ZieE13Tok" title="Concentration risk percentage">26% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z4PPaCdh7Wqk" title="Concentration risk percentage">12% of our purchases, respectively. For the nine months ended April 30, 2022, one vendor accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zUhwl3daw1ph" title="Concentration risk percentage">21% of our purchases. For the three months ended April 30, 2021, two vendors accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_z17JJz47nz4a" title="Concentration risk percentage">23% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zWyYFLrXtqgj" title="Concentration risk percentage">12% of our purchases, respectively. For the nine months ended April 30, 2021, one vendor accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zoaJDeCOhvN5" title="Concentration risk percentage">35% of our purchases. Accounts payable. As of April 30, 2022, our largest vendor accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zZHK0SvRU67" title="Concentration risk percentage">25% of the total accounts payable. As of April 30, 2021, our largest three vendors accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_z4sWzGYM2kLh" title="Concentration risk percentage">36%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zSxYRz6xUT15" title="Concentration risk percentage">17% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zvBf6BQxEGo3" title="Concentration risk percentage">14% of the total trade accounts payable, respectively. Segments We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

Revenue Recognition We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the contract with the customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">4.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocate the transaction price to the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">5.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognize revenue when (or as) each performance obligation is satisfied</td></tr> </table> Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid. Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of our revenue by product type for the nine months ended April 30, 2022 and 2021 is as follows: Summary of Revenue by Product <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_497_20210801__20220430_zryAucnhKPSk" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_498_20200801__20210430_zYNSzJdbi5bi" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PureHardSurfaceMember_zfHhoAyWDlIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,158,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,815,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zSmOP8R9wyD4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zeOyId52Xmp" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,409,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,841,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of our revenue by product type for the three months ended April 30, 2022 and 2021 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_492_20220201__20220430_zpk6cieogKNj" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49E_20210201__20210430_z8fhpFPynuy5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PureHardSurfaceMember_zRoYevgYx9Dh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">352,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">556,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zTGKxuI8CK56" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_zWkZHIWrojUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">497,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">556,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

A summary of our revenue by product type for the nine months ended April 30, 2022 and 2021 is as follows: Summary of Revenue by Product <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_497_20210801__20220430_zryAucnhKPSk" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_498_20200801__20210430_zYNSzJdbi5bi" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PureHardSurfaceMember_zfHhoAyWDlIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,158,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,815,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zSmOP8R9wyD4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zeOyId52Xmp" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,409,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,841,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of our revenue by product type for the three months ended April 30, 2022 and 2021 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_492_20220201__20220430_zpk6cieogKNj" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49E_20210201__20210430_z8fhpFPynuy5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PureHardSurfaceMember_zRoYevgYx9Dh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">352,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">556,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zTGKxuI8CK56" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_zWkZHIWrojUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">497,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">556,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1158000

2815000

251000

26000

1409000

2841000

352000

556000

145000

497000

556000

Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2022 and 2021, stock options, warrants and shares issuable under restricted stock unit awards of 7,391,625 and 10,358,765, respectively, have been excluded from the computation of diluted shares outstanding. <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zErokQH9oVy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_zZZYwAAKoJhk" style="width: 16%; text-align: right" title="Common stock option">6,179,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_z7HSIgv9Vva3" style="width: 16%; text-align: right" title="Common stock option">8,018,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zfkPLTeCJBVg" style="text-align: right" title="Restricted stock units">1,212,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqLK47p9bgce" style="text-align: right" title="Restricted stock units">2,012,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zadBSWGWzAeb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zCsi23BCZZK1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants">327,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430_zEBs2LOF8bo" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti dilutive securities">7,391,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430_zcS0GIVFx3xe" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti dilutive securities">10,358,765</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7391625

10358765

<p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zErokQH9oVy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_zZZYwAAKoJhk" style="width: 16%; text-align: right" title="Common stock option">6,179,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_z7HSIgv9Vva3" style="width: 16%; text-align: right" title="Common stock option">8,018,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zfkPLTeCJBVg" style="text-align: right" title="Restricted stock units">1,212,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqLK47p9bgce" style="text-align: right" title="Restricted stock units">2,012,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zadBSWGWzAeb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zCsi23BCZZK1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants">327,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210801__20220430_zEBs2LOF8bo" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti dilutive securities">7,391,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200801__20210430_zcS0GIVFx3xe" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti dilutive securities">10,358,765</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6179125

8018500

1212500

2012500

327765

7391625

10358765

Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49E_20220430_ziUTxo0YKwX5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_495_20210731_zhg2WVEskwv5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">April 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">July 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_maINzkyC_zx2rDRkzGWok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoods_iI_maINzkyC_zpTamjVbO7Qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">284,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">315,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtINzkyC_z2576UJXdwL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">332,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Inventories consist of the following: Schedule of Inventories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49E_20220430_ziUTxo0YKwX5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_495_20210731_zhg2WVEskwv5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">April 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">July 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_maINzkyC_zx2rDRkzGWok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoods_iI_maINzkyC_zpTamjVbO7Qh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">284,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">315,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtINzkyC_z2576UJXdwL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">332,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

17000

284000

315000

301000

332000

Share-Based Compensation We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.

<p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zb97jCIFF7ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and nine months ended April 30, 2022 and 2021, no impairment of long-lived assets was indicated or recorded.

Concentrations Gross product sales. For the three months ended April 30, 2022, three individual customers accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zR0bKyUlPGA7" title="Concentration risk percentage">29%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_z3aEqfhAt8Yb" title="Concentration risk percentage">14% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_zbNjgd9gfbL1" title="Concentration risk percentage">11% of our net product sales, respectively. For the nine months ended April 30, 2022, three customers accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zibojbdOz1E" title="Concentration risk percentage">14%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_zQcl6Va4scFl" title="Concentration risk percentage">12% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_zxuuzkUA70Y5" title="Concentration risk percentage">10% of our net product sales, respectively. For the three months ended April 30, 2021, three individual customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_z0vMCVLWkFXl" title="Concentration risk percentage">25%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_z5fa1WCqNqZh" title="Concentration risk percentage">12% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_z7PhsZXYl3Ag" title="Concentration risk percentage">11% of our net product sales. For the nine months ended April 30, 2021, two customers accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zr0nL5ggqsM7" title="Concentration risk percentage">18% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_zT57cp9vNsS9" title="Concentration risk percentage">10% of our net product sales, respectively. Accounts receivable. As of April 30, 2022, we had accounts receivable from four customers that comprised of <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zouATTQGH5Ge" title="Concentration risk percentage">15%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zmfvLO5jw741" title="Concentration risk percentage">14%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zcUWXVfTS24k" title="Concentration risk percentage">12 and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zo63j0eHXF05" title="Concentration risk percentage">11% of total accounts receivable, respectively. As of April 30, 2021, we had accounts receivable from three customers that comprised <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zpofD4fL15Z9" title="Concentration risk percentage">22%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zOXIFMlofZE2" title="Concentration risk percentage">15% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zeAhqksAk2Bh" title="Concentration risk percentage">13% of total accounts receivable, respectively. Purchases. For the three months ended April 30, 2022, two vendors accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zd1ZieE13Tok" title="Concentration risk percentage">26% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z4PPaCdh7Wqk" title="Concentration risk percentage">12% of our purchases, respectively. For the nine months ended April 30, 2022, one vendor accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zUhwl3daw1ph" title="Concentration risk percentage">21% of our purchases. For the three months ended April 30, 2021, two vendors accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_z17JJz47nz4a" title="Concentration risk percentage">23% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210201__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zWyYFLrXtqgj" title="Concentration risk percentage">12% of our purchases, respectively. For the nine months ended April 30, 2021, one vendor accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zoaJDeCOhvN5" title="Concentration risk percentage">35% of our purchases. Accounts payable. As of April 30, 2022, our largest vendor accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zZHK0SvRU67" title="Concentration risk percentage">25% of the total accounts payable. As of April 30, 2021, our largest three vendors accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_z4sWzGYM2kLh" title="Concentration risk percentage">36%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zSxYRz6xUT15" title="Concentration risk percentage">17% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zvBf6BQxEGo3" title="Concentration risk percentage">14% of the total trade accounts payable, respectively.

0.29

0.14

0.11

0.14

0.12

0.10

0.25

0.12

0.11

0.18

0.10

0.15

0.14

0.12

0.11

0.22

0.15

0.13

0.26

0.12

0.21

0.23

0.12

0.35

0.25

0.36

0.17

0.14

Segments We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

4. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivable. The standard will replace today’s “incurred loss” approach with an “expected loss” model , under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As small business filer, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 is not expected to have any impact on the Company’s consolidated financial statement presentation or disclosures. Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

5. Debt Receipt of CARES funding In April 2021, we were funded $<span id="xdx_900_eus-gaap--ProceedsFromLoans_c20210401__20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zncT2oJ7bkhh" title="Net proceeds from payroll protection program loan">239,000 under the Payroll Protection Program (“PPP”) through California Bank and Trust. The PPP was established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. <span id="xdx_90D_eus-gaap--DebtInstrumentDescription_c20210401__20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zgZM19alD3Cg" title="Debt description">The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. The amount of loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred for six months and will accrue interest at a fixed annual rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zKfqWx1Nnd0a" title="Debt instrument interest percentage">1.0% and carry a <span id="xdx_905_eus-gaap--DebtInstrumentTerm_dc_c20210429__20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zZfvjLekhNwk" title="Debt instrument term">two year maturity date. There is no prepayment penalty on the CARES Act Loan. During the nine months ended April 30, 2022, we applied and received loan forgiveness under the provisions of the CARES Act for the entire $<span id="xdx_90F_eus-gaap--ProceedsFromLoans_c20210801__20220430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_z5DtO2jeM5if" title="Net proceeds from payroll protection program loan">239,000 loan. This amount was recorded as a gain on extinguishment of indebtedness on the Condensed Consolidated Statement of Operations during the nine months ended April 30, 2022.

239000

The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs.

0.010

P2Y

239000

6. Stockholders’ Equity Restricted Stock Units The Company issues restricted stock unit awards (“RSUs”) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term. On October 4, 2018, the Board of Directors appointed Tom Myers as the Company’s Chief Operating Officer. In connection with Mr. Myers appointment, the Board agreed to grant him <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20181001__20181004__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MrMyersMember_zFn2zUrYO5h3" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period">500,000 RSUs upon the achievement by the Company of profitability for a fiscal quarter, after which such RSUs shall vest annually over the following three years. In May 2020, the <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20200501__20200531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MrMyersMember_zyRAOnDgWGHh" title="Share-based Compensation Arrangement by Share-based Payment">500,000 RSUs were formally granted to Mr. Myers due to the Company’s profitable April 30, 2020 fiscal quarter. During the nine months ended April 30, 2022 there were no Restricted Stock Units granted. As of July 31, 2021, the Company had granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210701__20210731__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTfWaHd011K1" title="Restricted stock options, granted">2,012,500 RSU’s of which <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210701__20210731__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znHiOTp0D9If" title="Restricted stock options vested">1,679,167 had vested. As of July 31, 2021, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20210731__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdZAgE3TQO55" title="Number of shares authorized fair values">333,333 RSU’s with a fair value of $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_iI_pp0p0_c20210731__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1NWUzpUoXTc" title="Number of shares authorized remained unvested">144,000, remained unvested. None of the shares vested under the RSUs had been issued as of July 31, 2021. During the nine months ended April 30, 2022 and 2021, the Company recognized $62,000 of compensation cost relating to RSU’s previously granted to Mr. Tom Myers, the Company’s Chief Operating Officer, which are being amortized over their <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210801__20220430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUx0x0vjla14" title="Vesting term">three year vesting term. As of April 30, 2022, there was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zt8BheqxnQde" title="Unrecognized non cash compensation cost relating">82,000 of unrecognized non-cash compensation cost related to the remaining <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20220131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjwxu7BuOIJa" title="Number of restricted stock shares">333,333 RSUs we expect to vest, which will be recognized over a weighted average period of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210801__20220430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJTNjTQDgghg" title="Weighted average period, restricted stock">1.0 year. During the nine months ended April 30, 2022, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zawwCVFhTZLh" title="Number of units, vested">800,000 RSUs were issued and delivered. Of the <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_z4Vdo2MhsOx1" title="Number of units, vested">1,212,500 RSUs outstanding as of April 30, 2022, <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuable_pid_c20210801__20220430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zdMdDM7KTkxc" title="Number of units, vested and issuable">879,167 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”. <p id="xdx_89E_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zs8Wjcmjdcfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of our restricted stock unit activity and related data is as follows: Schedule of Restricted Stock Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total RSU Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested and Issuable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at July 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zNf6Pqtjlme8" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">2,012,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zvwJtHr9EO3g" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">1,679,167</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zIqvoV65i0Da" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zwd2Okvog8T4" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zxGwuDUMIGdf" style="text-align: right" title="Issued">(800,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zOhwNfhCLSfh" style="text-align: right" title="Issued">(800,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zWgsdh8pYBbl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_z4i6umQZTBO8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding at April 30, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zwwltU8oBTPf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zpwiIeeWhzHd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">879,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Stock Option Plans 2007 Equity Incentive Plan In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20160201__20160229__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_zuQ2CKjgew03" title="Common stock shares increase under the plan">4,000,000 shares and extend the term of the 2007 Plan until <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20160201__20160229__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_za4ZvcefVMw8" title="Share-based compensation, expiration date">February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20160201__20160229__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_zU9xEgRfwXmb" title="Share-based compensation, vesting period">10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2022, there were approximately <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220430__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_zMfWop7FtNEb" title="Number of shares available for issuance under the plan">1,552,000 shares available for issuance under the 2007 Plan. 2017 Equity Incentive Plan In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zAgpRaHjumUi" title="Common stock shares increase under the plan">5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zO2f0LRANne3" title="Share-based compensation, vesting period">10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2022, there were approximately <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zsYUFBqOND81" title="Number of shares available for issuance under the plan">3,755,000 shares available for issuance under the 2017 Plan. During the nine months ended April 30, 2022, we authorized the issuance of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220430__srt--TitleOfIndividualAxis__custom--NewEmployeesMember_zYsCbHQEDoHe" title="Number of stock option authorized for issuance">170,000 stock options to new employees. The options have a fair value of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20210801__20220430__srt--TitleOfIndividualAxis__custom--NewEmployeesMember_zI2gfHlSgQaa" title="Fair value of stock option">36,000 as determined by the Black Scholes option pricing model, vest between <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtYxL_c20210801__20220430__srt--RangeAxis__srt--MinimumMember_z1mO1HME2lgg" title="Share-based compensation, vesting period::XDX::P1Y">one and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210801__20220430__srt--RangeAxis__srt--MaximumMember_zGwmnshjc0Ol" title="Share-based compensation, vesting period">three years and carry a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20210801__20220430__srt--TitleOfIndividualAxis__custom--NewEmployeesMember_zPVmvhHfgNO1" title="Share-based compensation, vesting period">ten year term. During the nine months ended April 30, 2021, we authorized the issuance of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--NewEmployeesMember_zBVOxlFapvD1" title="Number of stock option authorized for issuance">60,000 stock options to a consultant with a fair value of $<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedFairValues_iI_c20210430__srt--TitleOfIndividualAxis__custom--NewEmployeesMember_zc5NPdeEjZQ2" title="Number of stock option authorized fair value">48,000 as determined by the Black Scholes option pricing model. The options vest quarterly over <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20200801__20210430__srt--TitleOfIndividualAxis__custom--NewEmployeesMember__srt--RangeAxis__srt--MinimumMember_zRjhHxnDAjSg" title="Share-based compensation, vesting period">one year and carry a <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20200801__20210430__srt--TitleOfIndividualAxis__custom--NewEmployeesMember_zfsWdrdIpHK9" title="Share-based compensation, vesting period">five year term. There were no stock option grants during the three months ended April 30, 2022 and 2021. A summary of our stock option activity is as follows: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at July 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z6M1RnK0rDmi" style="width: 14%; text-align: right" title="Options Outstanding Shares, Beginning Balance">8,644,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zf7CBmJRn2y9" style="width: 14%; text-align: right" title="Weighted- Average Exercise Price Outstanding, Beginning Balance">0.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zOWp4fflJO5g" style="width: 14%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning Balance">124,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zEFJxDElJKN4" style="text-align: right" title="Options Granted, Shares">170,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z7NIsbQDc6si" style="text-align: right" title="Weighted- Average Exercise Price Granted">0.29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantsAggregateIntrinsicValue_iI_c20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z5xfyTYVQchk" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Granted">2,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zNwIu1TgAcDi" style="text-align: right" title="Options Exercised, Shares">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zpJQfpAqQTOl" style="text-align: right" title="Weighted- Average Exercise Price Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z1Dh5qhI3GDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Cancelled, Shares">(2,635,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zQHng35XlOMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted- Average Exercise Price Cancelled">1.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at April 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z9oq1t69ejr3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Shares, Ending Balance">6,179,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zGKFUJLDzX79" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding, Ending Balance">0.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zuMhSz2xMDqh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending Balance">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted-average remaining contractual term of options outstanding at April 30, 2022 was <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210801__20220430_zdpDON3vLkIe" title="Weighted average contractual term">6.64 years. At April 30, 2022, options to purchase 5,466,625 shares of common stock were exercisable. These options had a weighted-average exercise price of $<span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220430_zTqhWJxhDcwd" title="Weighted average exercise price">0.64 and a weighted average remaining contractual term of <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210801__20220430_zAqPNabBzZR4" title="Weighted average contractual term">6.31 years. The total unrecognized compensation cost related to unvested stock option grants as of April 30, 2022 was approximately $150,000 and the weighted average period over which these grants are expected to vest is <span id="xdx_90F_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermGrants_dtY_c20210801__20220430_z6825HFhTgZ5" title="Weighted average contractual term grants">0.83 years. For the nine months ended April 30, 2022 share-based compensation expense for stock options that vested during the period was $431,000. For the nine months ended April 30, 2021 share-based compensation expense for stock options that vested during the period was $621,000. We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: <p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJO2e8qR0yYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Fair Value Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Nine Months Ended April 30, 2022</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Nine Months Ended April 30, 2021</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">88.35.</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">% </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">104.93.</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.17</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.18</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Expected life</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.59 years</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.81 years</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation. The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

500000

2012500

1679167

333333

144000

62000

P3Y

82000

333333

P1Y

800000

1212500

879167

<p id="xdx_89E_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zs8Wjcmjdcfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of our restricted stock unit activity and related data is as follows: Schedule of Restricted Stock Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total RSU Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested and Issuable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at July 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zNf6Pqtjlme8" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">2,012,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zvwJtHr9EO3g" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">1,679,167</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zIqvoV65i0Da" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zwd2Okvog8T4" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zxGwuDUMIGdf" style="text-align: right" title="Issued">(800,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zOhwNfhCLSfh" style="text-align: right" title="Issued">(800,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zWgsdh8pYBbl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_z4i6umQZTBO8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding at April 30, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--TotalRSUSharesMember_zwwltU8oBTPf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210801__20220430__us-gaap--AwardTypeAxis__custom--VestedAndIssuableMember_zpwiIeeWhzHd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">879,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

2012500

1679167

-800000 -800000

1212500

879167

4000000

2026-02-04

P10Y

1552000

5000000

P10Y

3755000

170000

36000

P3Y

P10Y

60000

48000

P1Y

P5Y

A summary of our stock option activity is as follows: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at July 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z6M1RnK0rDmi" style="width: 14%; text-align: right" title="Options Outstanding Shares, Beginning Balance">8,644,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zf7CBmJRn2y9" style="width: 14%; text-align: right" title="Weighted- Average Exercise Price Outstanding, Beginning Balance">0.76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zOWp4fflJO5g" style="width: 14%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning Balance">124,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zEFJxDElJKN4" style="text-align: right" title="Options Granted, Shares">170,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z7NIsbQDc6si" style="text-align: right" title="Weighted- Average Exercise Price Granted">0.29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantsAggregateIntrinsicValue_iI_c20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z5xfyTYVQchk" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Granted">2,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zNwIu1TgAcDi" style="text-align: right" title="Options Exercised, Shares">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zpJQfpAqQTOl" style="text-align: right" title="Weighted- Average Exercise Price Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z1Dh5qhI3GDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Cancelled, Shares">(2,635,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zQHng35XlOMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted- Average Exercise Price Cancelled">1.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at April 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_z9oq1t69ejr3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Shares, Ending Balance">6,179,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zGKFUJLDzX79" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding, Ending Balance">0.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20210801__20220430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zuMhSz2xMDqh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending Balance">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8644125

0.76

124000

170000

0.29

2000

2635000

1.05

6179125

0.62

P6Y7M20D

5466625

0.64

P6Y3M21D

150000

P0Y9M29D

431000

621000

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJO2e8qR0yYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Fair Value Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Nine Months Ended April 30, 2022</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Nine Months Ended April 30, 2021</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">88.35.</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">% </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">104.93.</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.17</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.18</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Expected life</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.59 years</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.81 years</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

0.8835

1.0493

0.0117

0.0018

0.000

P5Y7M2D

P2Y9M21D

7. Related Party Transactions As of April 30, 2022 and April 30, 2021, accounts payable include $136,000 and $63,600 in board fees due to officers and directors, respectively.

136000

63600

8. Commitments and Contingencies COVID-19 The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we previously benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We subsequently experienced an abatement in such demand and cannot assure you that demand will stabilize. Additionally, we are beginning to experience supply chain issues with our various plastic packaging configurations and citric acid. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team. Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure. The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 125 157 1 false 38 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://purebio.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://purebio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://purebio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://purebio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://purebio.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://purebio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://purebio.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity and Going Concern Sheet http://purebio.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://purebio.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Recent Accounting Pronouncements Sheet http://purebio.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 00000011 - Disclosure - Debt Sheet http://purebio.com/role/Debt Debt Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders??? Equity Sheet http://purebio.com/role/StockholdersEquity Stockholders??? Equity Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://purebio.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://purebio.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Significant Accounting Policies (Policies) Sheet http://purebio.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://purebio.com/role/SignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Tables) Sheet http://purebio.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://purebio.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Stockholders??? Equity (Tables) Sheet http://purebio.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://purebio.com/role/StockholdersEquity 17 false false R18.htm 00000018 - Disclosure - Liquidity and Going Concern (Details Narrative) Sheet http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative Liquidity and Going Concern (Details Narrative) Details http://purebio.com/role/LiquidityAndGoingConcern 18 false false R19.htm 00000019 - Disclosure - Summary of Revenue by Product (Details) Sheet http://purebio.com/role/SummaryOfRevenueByProductDetails Summary of Revenue by Product (Details) Details 19 false false R20.htm 00000020 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 20 false false R21.htm 00000021 - Disclosure - Schedule of Inventories (Details) Sheet http://purebio.com/role/ScheduleOfInventoriesDetails Schedule of Inventories (Details) Details 21 false false R22.htm 00000022 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://purebio.com/role/SignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - Debt (Details Narrative) Sheet http://purebio.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://purebio.com/role/Debt 23 false false R24.htm 00000024 - Disclosure - Schedule of Restricted Stock Activity (Details) Sheet http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails Schedule of Restricted Stock Activity (Details) Details 24 false false R25.htm 00000025 - Disclosure - Schedule of Stock Option Activity (Details) Sheet http://purebio.com/role/ScheduleOfStockOptionActivityDetails Schedule of Stock Option Activity (Details) Details 25 false false R26.htm 00000026 - Disclosure - Schedule of Fair Value Assumptions (Details) Sheet http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails Schedule of Fair Value Assumptions (Details) Details 26 false false R27.htm 00000027 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://purebio.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://purebio.com/role/StockholdersEquityTables 27 false false R28.htm 00000028 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://purebio.com/role/RelatedPartyTransactions 28 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm pure-20220430.xsd pure-20220430_cal.xml pure-20220430_def.xml pure-20220430_lab.xml pure-20220430_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 46 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 125, "dts": { "calculationLink": { "local": [ "pure-20220430_cal.xml" ] }, "definitionLink": { "local": [ "pure-20220430_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "pure-20220430_lab.xml" ] }, "presentationLink": { "local": [ "pure-20220430_pre.xml" ] }, "schema": { "local": [ "pure-20220430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 287, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 49, "http://purebio.com/20220430": 15, "http://xbrl.sec.gov/dei/2022": 5, "total": 69 }, "keyCustom": 10, "keyStandard": 147, "memberCustom": 24, "memberStandard": 12, "nsprefix": "PURE", "nsuri": "http://purebio.com/20220430", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://purebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Recent Accounting Pronouncements", "role": "http://purebio.com/role/RecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Debt", "role": "http://purebio.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Stockholders\u2019 Equity", "role": "http://purebio.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Related Party Transactions", "role": "http://purebio.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Commitments and Contingencies", "role": "http://purebio.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://purebio.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://purebio.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Stockholders\u2019 Equity (Tables)", "role": "http://purebio.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "span", "p", "PURE:LiquidityAndGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Liquidity and Going Concern (Details Narrative)", "role": "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "shortName": "Liquidity and Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PURE:LiquidityAndGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "lang": null, "name": "PURE:NetCashProvidedByUsedInOperatingAndInvestingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfProductInformationTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-02-012022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Summary of Revenue by Product (Details)", "role": "http://purebio.com/role/SummaryOfRevenueByProductDetails", "shortName": "Summary of Revenue by Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfProductInformationTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-02-012022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://purebio.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "role": "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-012022-04-30_custom_CommonStockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Schedule of Inventories (Details)", "role": "http://purebio.com/role/ScheduleOfInventoriesDetails", "shortName": "Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Significant Accounting Policies (Details Narrative)", "role": "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-08-012021-04-30", "decimals": "INF", "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Segments", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-04-30_custom_CaliforniaBankAndTrustMember_custom_PayrollProtectionProgramMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLoans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Debt (Details Narrative)", "role": "http://purebio.com/role/DebtDetailsNarrative", "shortName": "Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-04-30_custom_CaliforniaBankAndTrustMember_custom_PayrollProtectionProgramMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLoans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-07-31_custom_TotalRSUSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Schedule of Restricted Stock Activity (Details)", "role": "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "shortName": "Schedule of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-07-31_custom_TotalRSUSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-07-31_custom_TwoThousandSeventeenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Schedule of Stock Option Activity (Details)", "role": "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "shortName": "Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-07-31_custom_TwoThousandSeventeenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Schedule of Fair Value Assumptions (Details)", "role": "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails", "shortName": "Schedule of Fair Value Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://purebio.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30_custom_BoardFeesDuetoOfficersAndDirectorsMember", "decimals": "0", "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://purebio.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-02-012022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://purebio.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-02-012022-04-30", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-07-31_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "role": "http://purebio.com/role/StatementOfStockholdersEquity", "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-07-31_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-02-012022-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://purebio.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Basis of Presentation", "role": "http://purebio.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "PURE:LiquidityAndGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Liquidity and Going Concern", "role": "http://purebio.com/role/LiquidityAndGoingConcern", "shortName": "Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "PURE:LiquidityAndGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Significant Accounting Policies", "role": "http://purebio.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-01to2022-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "PURE_AccountsPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable [Member]", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayablesMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_BoardFeesDuetoOfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board Fees Due to Officers and Directors [Member]", "label": "Board Fees Due to Officers and Directors [Member]" } } }, "localname": "BoardFeesDuetoOfficersAndDirectorsMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CaliforniaBankAndTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "California Bank and Trust [Member]", "label": "California Bank and Trust [Member]" } } }, "localname": "CaliforniaBankAndTrustMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CommonStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Option [Member]", "label": "Common Stock Option [Member]" } } }, "localname": "CommonStockOptionMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "PURE_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Four [Member]", "label": "Customer Four [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One [Member]", "label": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Three [Member]", "label": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Two [Member]", "label": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_DisclosureLiquidityAndGoingConcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity And Going Concern" } } }, "localname": "DisclosureLiquidityAndGoingConcernAbstract", "nsuri": "http://purebio.com/20220430", "xbrltype": "stringItemType" }, "PURE_IndividualCustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Customer One [Member]", "label": "Individual Customer One [Member]" } } }, "localname": "IndividualCustomerOneMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_IndividualCustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Customer Three [Member]", "label": "Individual Customer Three [Member]" } } }, "localname": "IndividualCustomerThreeMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_IndividualCustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Customer Two [Member]", "label": "Individual Customer Two [Member]" } } }, "localname": "IndividualCustomerTwoMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_LiquidityAndGoingConcernTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity And Going Concern [Text Block]", "label": "Liquidity and Going Concern" } } }, "localname": "LiquidityAndGoingConcernTextBlock", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "PURE_MrMyersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr. Myers [Member]", "label": "Mr. Myers [Member]" } } }, "localname": "MrMyersMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_NetCashProvidedByUsedInOperatingAndInvestingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net cash provided by (used) in operating and investing activities.", "label": "Net cash provided by (used) in operating and investing activities" } } }, "localname": "NetCashProvidedByUsedInOperatingAndInvestingActivities", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PURE_NetProceedsFromPayrollProtectionProgramLoan": { "auth_ref": [], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net proceeds from payroll protection program loan" } } }, "localname": "NetProceedsFromPayrollProtectionProgramLoan", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PURE_NewEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Employees [Member]", "label": "New Employees [Member]" } } }, "localname": "NewEmployeesMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_PayrollProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payroll Protection Program [Member]", "label": "Payroll Protection Program [Member]" } } }, "localname": "PayrollProtectionProgramMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_PurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchases [Member]", "label": "Purchases [Member]" } } }, "localname": "PurchasesMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_PureHardSurfaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PURE Hard Surface [Member]", "label": "PURE Hard Surface [Member]" } } }, "localname": "PureHardSurfaceMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "PURE_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period.", "label": "Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "PURE_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instuments Other Than Options Vested And Issuable", "label": "Number of units, vested and issuable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuable", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PURE_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedFairValues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Fair Values", "label": "Number of stock option authorized fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedFairValues", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PURE_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantsAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By ShareBased Payment Award Options Vested And Expected To Vest Grants Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantsAggregateIntrinsicValue", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "PURE_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term Grants", "label": "Weighted average contractual term grants" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermGrants", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "PURE_SilVerionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SILV?RION [Member]", "label": "SILVERION [Member]" } } }, "localname": "SilVerionMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "PURE_StockIssuedDuringPeriodIssuanceOfCommonStockForSharesVestedRestrictedStockUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Issuance Of Common Stock For Shares Vested Restricted Stock Units", "label": "Issuance of common stock for vested restricted stock units, shares" } } }, "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockForSharesVestedRestrictedStockUnits", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PURE_StockIssuedDuringPeriodIssuanceOfCommonStockForVestedRestrictedStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period issuance of common stock for vested restricted stock units.", "label": "Issuance of common stock for vested restricted stock units" } } }, "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockForVestedRestrictedStockUnits", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PURE_TotalRSUSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total RSU Shares [Member]", "label": "Total RSU Shares [Member]" } } }, "localname": "TotalRSUSharesMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "PURE_TwoThousandAndSevenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2007 Equity Incentive Plan [Member]", "label": "2007 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndSevenEquityIncentivePlanMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_TwoThousandSeventeenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Equity Incentive Plan [Member]", "label": "2017 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandSeventeenEquityIncentivePlanMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_VendorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor One [Member]", "label": "Vendor One [Member]" } } }, "localname": "VendorOneMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_VendorThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor Three [Member]", "label": "Vendor Three [Member]" } } }, "localname": "VendorThreeMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_VendorTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor Two [Member]", "label": "Vendor Two [Member]" } } }, "localname": "VendorTwoMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_VestedAndIssuableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vested and Issuable [Member]", "label": "Vested and Issuable [Member]" } } }, "localname": "VestedAndIssuableMember", "nsuri": "http://purebio.com/20220430", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r399", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r135", "r236", "r238", "r372" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r159", "r160", "r161", "r162", "r178", "r211", "r241", "r243", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r370", "r373", "r385", "r386" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r159", "r160", "r161", "r162", "r178", "r211", "r241", "r243", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r370", "r373", "r385", "r386" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r135", "r236", "r238", "r372" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r133", "r160", "r161", "r236", "r237", "r342", "r369", "r371" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r133", "r160", "r161", "r236", "r237", "r342", "r369", "r371" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r154", "r159", "r160", "r161", "r162", "r178", "r211", "r240", "r241", "r243", "r273", "r274", "r275", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r370", "r373", "r385", "r386" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r154", "r159", "r160", "r161", "r162", "r178", "r211", "r240", "r241", "r243", "r273", "r274", "r275", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r370", "r373", "r385", "r386" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r81", "r86", "r158", "r242" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r81", "r86", "r158", "r242", "r332" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r136", "r326" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r137", "r138" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r69", "r70", "r71", "r280", "r281", "r282", "r296" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "Share-based compensation expense - restricted stock units" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Share-based compensation expense - stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti dilutive securities", "verboseLabel": "Dilutive common share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r66", "r117", "r126", "r131", "r142", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r289", "r291", "r304", "r329", "r331", "r348", "r361" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r29", "r66", "r142", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r289", "r291", "r304", "r329", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r246", "r247", "r248", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r270", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r10", "r58" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r52", "r58", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r52", "r58", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r52", "r308" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r352", "r366" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r155", "r156", "r157", "r163", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r69", "r70", "r296" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.01 par value: 150,000,000 shares authorized, 88,023,141 shares issued and outstanding at April 30, 2022, and 87,223,141 shares issued and outstanding at July 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Share-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r108", "r109", "r135", "r302", "r303", "r383" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r108", "r109", "r135", "r302", "r303", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r108", "r109", "r135", "r302", "r303", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r104", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r108", "r109", "r135", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r108", "r109", "r135", "r302", "r303", "r383" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r48", "r342" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r107", "r135" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r63", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r192", "r199", "r200", "r201", "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r65", "r67", "r175", "r176", "r177", "r178", "r179", "r180", "r182", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r197", "r198", "r202", "r203", "r204", "r205", "r317", "r349", "r350", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r12", "r14", "r224", "r349", "r350", "r358", "r360" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r34", "r176" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument interest percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r35", "r65", "r67", "r175", "r176", "r177", "r178", "r179", "r180", "r182", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r197", "r198", "r202", "r203", "r204", "r205", "r317" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r56", "r152" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r46", "r78", "r79", "r80", "r81", "r82", "r89", "r91", "r93", "r94", "r95", "r98", "r99", "r297", "r298", "r354", "r368" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized non-cash compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r40", "r41", "r42", "r69", "r70", "r71", "r75", "r83", "r85", "r101", "r143", "r223", "r225", "r280", "r281", "r282", "r284", "r285", "r296", "r309", "r310", "r311", "r312", "r313", "r314", "r321", "r374", "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r151", "r343" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patents, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r56", "r206", "r207" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment of indebtedness, net", "negatedLabel": "Gain on extinguishment of indebtedness" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r47", "r66", "r117", "r125", "r127", "r130", "r132", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r304" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r55" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r55" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r55" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r55" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r43", "r116", "r315", "r316", "r355" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r22" ], "calculation": { "http://purebio.com/role/ScheduleOfInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r27", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://purebio.com/role/ScheduleOfInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r25", "r61", "r100", "r146", "r147", "r148", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r23" ], "calculation": { "http://purebio.com/role/ScheduleOfInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r66", "r142", "r304", "r331", "r351", "r364" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r33", "r66", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r290", "r291", "r292", "r304", "r329", "r330", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r31", "r65" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loan payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r52" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r52" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r52", "r54", "r57" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r38", "r39", "r42", "r45", "r57", "r66", "r74", "r78", "r79", "r80", "r81", "r84", "r85", "r92", "r117", "r125", "r127", "r130", "r132", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r298", "r304", "r353", "r367" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://purebio.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://purebio.com/role/StatementOfStockholdersEquity", "http://purebio.com/role/StatementsOfCashFlows", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r72", "r73", "r76", "r77", "r86", "r87", "r88", "r140", "r141", "r144", "r145", "r286", "r287", "r288", "r295", "r299", "r300", "r301", "r305", "r306", "r307", "r318", "r319", "r320", "r322", "r344", "r345", "r346", "r377", "r378", "r379", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating costs and expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r117", "r125", "r127", "r130", "r132" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r246", "r247", "r248", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r270", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r246", "r247", "r248", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r270", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15", "r209" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15", "r209" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r28", "r149", "r150" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "verboseLabel": "Net proceeds from payroll protection program loan" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r153", "r331", "r357", "r365" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r323", "r324", "r325", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r283", "r341", "r387" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r10", "r59", "r347", "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "periodEndLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r10", "r58", "r59", "r347", "r362" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r225", "r331", "r363", "r377", "r381" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Cumulative net loss" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r69", "r70", "r71", "r75", "r83", "r85", "r143", "r280", "r281", "r282", "r284", "r285", "r296", "r374", "r376" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r114", "r115", "r124", "r128", "r129", "r133", "r134", "r135", "r235", "r236", "r342" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r62", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r44", "r66", "r114", "r115", "r124", "r128", "r129", "r133", "r134", "r135", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r304", "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r108", "r135" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r24", "r25", "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.", "label": "Summary of Revenue by Product" } } }, "localname": "ScheduleOfProductInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r270", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r250", "r265", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Fair Value Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Restricted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r118", "r119", "r120", "r121", "r122", "r123", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based compensation, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted", "verboseLabel": "Restricted stock options, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Number of restricted stock shares", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average period, restricted stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Number of units, vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Fair value of stock option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Share-based compensation, expiration date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Common stock shares increase under the plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of stock option authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of shares available for issuance under the plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Options issued to purchase common stock exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Options Cancelled, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options Granted, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding Shares, Ending Balance", "periodStartLabel": "Options Outstanding Shares, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted- Average Exercise Price Outstanding, Ending Balance", "periodStartLabel": "Weighted- Average Exercise Price Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending Balance", "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r246", "r247", "r248", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r270", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted- Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted- Average Exercise Price Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted- Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Number of shares authorized remained unvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Weighted average exercise price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average contractual term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average contractual term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r60", "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r37", "r40", "r41", "r42", "r69", "r70", "r71", "r75", "r83", "r85", "r101", "r143", "r223", "r225", "r280", "r281", "r282", "r284", "r285", "r296", "r309", "r310", "r311", "r312", "r313", "r314", "r321", "r374", "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://purebio.com/role/StatementOfStockholdersEquity", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r69", "r70", "r71", "r101", "r342" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://purebio.com/role/StatementOfStockholdersEquity", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r223", "r225", "r256" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Issuance of common stock upon the exercise of stock options, shares", "verboseLabel": "Options Exercised, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r37", "r223", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuance of common stock upon the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r19", "r20", "r66", "r139", "r142", "r304", "r331" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r64", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r226", "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r102", "r103", "r105", "r106", "r110", "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Shares used in computing basic and diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r388": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r389": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r390": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r391": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r392": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r393": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r396": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r397": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r398": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r399": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r400": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r401": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r402": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r403": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r404": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r405": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r406": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r407": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" } }, "version": "2.1" } ZIP 47 0001493152-22-016732-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-016732-xbrl.zip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end